HMO-producing microorganisms with improved robustness to glucose gradients

By manipulating citrate synthase, phosphoenol pyruvate carboxylase and isocitrate lyase regulators, the problem of acetate production in large-scale fermentation is solved, and the yield and cell robustness of human milk oligosaccharides are improved. .

CN119095975APending Publication Date: 2024-12-06DSM IP ASSETS BV
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202380036488.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-04-27
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

During large-scale fermentation, heterogeneity caused by inefficient mixing leads to cell overflow metabolism, producing large amounts of acetate or ethanol, affecting human milk oligosaccharide (HMO) production and cell robustness.

Method used

The production of acetate is reduced by manipulating the expression, overexpression or reduction of citrate synthase (gltA), phosphoenolpyruvate carboxylase (ppc), and isocitrate lyase regulator (iclR), and Improve cell robustness to glucose gradient.

Benefits of technology

It effectively reduces the formation of acetate, improves the yield of HMO and the robustness of cells, especially when the glucose gradient changes, reduces the production of acetate, and avoids the performance degradation during the fermentation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005102280070000101
    Figure BDA0005102280070000101
  • Figure BDA0005102280070000111
    Figure BDA0005102280070000111
  • Figure BDA0005102280070000112
    Figure BDA0005102280070000112
Patent Text Reader

Abstract

The present disclosure relates to improved strains for large scale production of human milk oligosaccharides (HMOs). These strains are genetically engineered to produce less acetate and / or ethanol during large scale fermentation, particularly when a gradient with excess carbon source is encountered in the fermenter.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to the production of human milk oligosaccharides (HMO) using genetically engineered cells that produce less acetate or ethanol during fermentation. In particular, the present disclosure relates to genetically modified cells that overexpress citrate synthase (gltA) while overexpressing phosphoenolpyruvate carboxylase (ppc), and / or reduce or eliminate the expression of isocitrate lyase regulator (iclR). Background Art

[0002] The design and construction of bacterial cell factories for the production of human milk oligosaccharides (HMOs) is critical to improving the cellular robustness for future large-scale industrial fermentations of HMO production.

[0003] For HMO production cell lines, rational strain engineering principles are commonly applied to individual bacterial cells. Such principles generally involve a) introducing the desired biosynthetic pathway into the host, b) increasing the cellular pool of relevant active sugars required as donors in the desired reaction, c) enhancing lactose import through the natural lactose permease LacY, and d) introducing appropriate glycosyltransferases to promote the biosynthetic production of oligosaccharides (reviewed in Bych et al., 2019, Current Opinion in Biotechnology 56: 130-137).

[0004] One of the major challenges in expanding aerobic fermentation processes is the heterogeneity caused by inefficient mixing. Perfect mixing of large-scale bioreactor volumes of about 1000L and larger is not feasible, and therefore, gradients of substrates (Bylund et al., 1998 Bioprocess Engineering, 18 (3), 171-180), nutrients, pH values, and dissolved gases may be formed. Under such conditions, the culture is exposed to a variety of harsh conditions and heterogeneity. Glucose gradients have been shown to trigger overflow metabolism of Escherichia coli in high glucose concentration areas (Lara et al., 2009 Biotech Bioengineering 104 (6), 1153-1161), as well as the increase in cell maintenance requirements, ultimately leading to performance degradation.

[0005] Due to the overflow metabolism of glucose, acetate formation is the main byproduct of aerobic fermentation in some microorganisms. Increased acetate concentrations inhibit growth rate and recombinant protein production, and may even cause fermentation batch failures, resulting in serious economic losses. Therefore, eliminating acetate formation is an important goal of industrial production. In other organisms such as yeast, overflow metabolism leads to ethanol formation, which may have an inhibitory effect similar to acetate. For a review of overflow metabolites in different organisms, see Taymaz Nikerel and Lara 2022Microorganisms 10,43.

[0006] De Maeseneire 2006 Biotechnol Lett 28:1945-1953 describes that the effect of reduced acetate and increased cell density in E. coli cells is the upregulation of citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc). This article is not related to HMO production and does not describe an increase in robustness to glucose gradients.

[0007] Liao et al., 2021 Biotechnology & Biotechnological Equipment, 35, 425-436, describe the deletion of iclR and / or arcA in 2'FL production strains. Here, iclR deletion significantly reduced 2'FL production.

[0008] In summary, acetate production in large-scale fermentation is a challenge that has been addressed by manipulating the host cell by redirecting carbon flux to the TCA cycle to reduce pyruvate to acetate formation. However, for HMO production, this issue has not yet been addressed without compromising HMO yield. Summary of the invention

[0009] The present disclosure relates to a host cell capable of producing HMOs, wherein the cell is manipulated to produce less acetate during fermentation, and the host cell also exhibits increased robustness when subjected to a glucose gradient.

[0010] One aspect of the present disclosure relates to a genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs), wherein the cell comprises the following modifications a) overexpression of citrate synthase (gltA), and b) one or more heterologous nucleic acids encoding one or more glycosyltransferases, and c) at least one biosynthetic pathway for preparing active sugar nucleotides that can be used as glycosyl donors by the glycosyltransferases of b). In addition, the genetically modified cell may comprise a further modification d) having at least one of the following modifications: i) overexpression of phosphoenolpyruvate carboxylase (ppc), and / or ii) reduced or absent expression of isocitrate lyase regulator (iclR).

[0011] The genetically modified cells according to the present disclosure may further comprise a promoter element that independently controls the expression of a natural or recombinant nucleic acid encoding citrate synthase (gltA) and / or a natural or recombinant nucleic acid encoding phosphoenolpyruvate carboxylase (ppc). In the case where the promoter element controls a native gene, it is stronger than the native promoter, thereby resulting in overexpression of the native gene.

[0012] Genetically modified cells according to the present disclosure can be microorganisms, such as bacteria or fungi, wherein the fungi can be selected from yeast cells, such as Komagataella, Kluyveromyces, Yarrowia, Pichia, Saccaromyces, Schizosaccharomyces or Hansenula, or filamentous fungi selected from Aspergillus, Fusarium or Thricoderma, and the bacteria can be selected from the exemplary groups of Escherichia sp., Bacillus sp., Lactobacillus sp., Corynebacterium sp. and Campylobacter sp.. Therefore, genetically modified cells according to the present disclosure can be Escherichia coli.

[0013] The genetically modified cells of the present disclosure can be used to produce HMOs or mixtures of HMOs.

[0014] Another aspect of the present disclosure relates to a method for producing human milk oligosaccharides (HMOs), comprising the steps of: a) providing a genetically modified cell of the present disclosure, and b) culturing the cell according to (a) in a suitable cell culture medium to produce the HMOs. Preferably, the acetate formation produced by the genetically modified cell of the present disclosure is at least 30% lower than that produced by the genetically modified cell without overexpressing citrate synthase (gltA). Even more preferably, the acetate formation produced by the genetically modified cell of the present disclosure is at least 40% lower than that produced by the genetically modified cell without overexpressing citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc) or without overexpressing citrate synthase (gltA) and the expression of isocitrate lyase regulator (iclR) is eliminated.

[0015] Various exemplary embodiments and details are described below with reference to the accompanying drawings and related sequences. It should be noted that the accompanying drawings are intended only to facilitate the description of the embodiments. They are not intended to be exhaustive descriptions of the present disclosure or to limit the scope of the present disclosure. In addition, the illustrated embodiments do not need to have all the aspects or advantages shown. The aspects or advantages described in conjunction with a particular embodiment are not necessarily limited to that embodiment, and may be practiced in any other embodiment, even if not shown as such, or not so explicitly described. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 : Formation of acetate in culture after glucose pulse (Example 3). Samples were collected and quantified for acetate before pulse addition (t=-5 min), at addition (t=0), and frequently until 90 min. Mutant experiments were performed in duplicate (n=2) and control strains in triplicate (n=3).

[0017] Figure 2 : Comparison of product formation and growth in fed-batch fermentations of Examples 2 and 3. The vertical grey dashed line indicates the window in Example 3 when a glucose pulse was added to the fermentation.

[0018] Figure 3 : Simplified central carbon metabolism and 2'FL production pathway in E. coli. Gene targets that increase carbon flux from pyruvate to TCA are marked in bold. DETAILED DESCRIPTION

[0019] The present disclosure addresses the biotechnological challenges of in vivo HMO production, particularly large-scale production, where heterogeneity arises in fermentation due to inefficient mixing, which can lead to overflow metabolism in cells. Overflow metabolism in many bacteria leads to high acetate formation and affects product yields. In many yeasts, overflow metabolism leads to high ethanol formation, which also affects product yields, and in some species, both acetate and ethanol formation is observed (Taymaz-Nikerel and Lara 2022 Microorganists 10, 43).

[0020] In other words, the genetically modified cells encompassed by the present disclosure provide a host cell that produces less acetate or ethanol during fermentation and exhibits increased robustness to glucose gradients.

[0021] In an example of this application, genes related to the TCA cycle have been investigated for their ability to reduce acetic acid / acetate formation during fermentation without reducing HMO production, as well as their ability to withstand glucose pulses. Manipulation of one or more of the following genes, either alone or in combination, was found to have an effect on acetate formation: a) citrate synthase (gltA) and b) phosphoenolpyruvate carboxylase (ppc) and c) isocitrate lyase regulator (iclR). Figure 3 Shown are pathways affected in a modified cell of the present disclosure, wherein the cell is a 2'FL producing cell.

[0022] In one embodiment of the present disclosure, the genetically modified cell is capable of producing one or more HMOs and it overexpresses citrate synthase (gltA), preferably in combination with overexpression of phosphoenolpyruvate carboxylase (ppc). As shown in Example 1, this causes a reduction of more than 40% in acetate, without a significant reduction in HMO production, compared to the same strain without these modifications (i.e., without overexpressing glta and pcc). In addition, the strain is not affected by the glucose gradient introduced into the fermentation via glucose pulses (Example 4).

[0023] In another embodiment of the present disclosure, the genetically modified cell is capable of producing one or more HMOs and overexpresses citrate synthase (gltA), preferably, the isocitrate lyase regulator (iclR) has also been mutated to prevent expression of functional iclR. As shown in Example 1, this results in a reduction of more than 70% in acetate, while HMO production is not reduced, and may even be increased, compared to the same strain without these modifications (i.e., not overexpressing glta and not containing an iclR deletion). In addition, the strain is not affected by the glucose gradient introduced into the fermentation via glucose pulses (Example 4).

[0024] In further embodiments of the present disclosure, the genetically modified cell is capable of producing one or more HMOs and overexpresses citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc), and the isocitrate lyase regulator (iclR) has been mutated to prevent expression of functional iclR.

[0025] Citrate synthase (gltA)

[0026] Citrate synthase is an enzyme belonging to EC2.3.3.1 and is present in almost all living cells. Citrate synthase is the first step of the citric acid cycle, in which it catalyzes the condensation reaction of the two-carbon acetate residue and the four-carbon oxaloacetate molecule from acetyl-CoA to form six-carbon citric acid. Citrate synthase is encoded by the gltA gene in Escherichia coli and Corynebacterium, but can have different names and isomers in other organisms, such as CIT 1, CIT2 and CIT 3 in Saccharomyces cerevisiae, or citA, citZ, ctsA or mmgD in Bacillus. In the context of the present disclosure, gltA refers to the gene encoding citrate synthase, regardless of the strain encoding it.

[0027] In one embodiment of the present disclosure, citrate synthase can be overexpressed, for example, by placing the native gltA gene under the control of a promoter stronger than the native promoter, or by inserting a recombinant nucleic acid encoding citrate synthase into the cell. In a preferred embodiment, the promoter controlling the expression of citrate synthase is selected from Table 10.

[0028] In one embodiment, the nucleic acid encoding citrate synthase comprises or consists of the amino acid sequence of SEQ ID NO: 1, or comprises or consists of an amino acid sequence that is at least 80%, such as at least 85%, such as at least 90%, such as at least 95% or such as at least 99% identical to SEQ ID NO: 1.

[0029] The recombinant nucleic acid encoding citrate synthase can be expressed in vitro, for example, carried by a plasmid or integrated into the genome of a genetically modified cell. For large-scale production, integration into the genome is preferred in order to avoid selection pressure to maintain the plasmid in the cell.

[0030] Phosphoenolpyruvate carboxylase (ppc)

[0031] Phosphoenolpyruvate carboxylase (also referred to as PEP carboxylase, PEPCase or PEPC) is an enzyme belonging to EC4.1.1.31, which is present in plants and bacteria. Phosphoenolpyruvate carboxylase catalyzes the formation of phosphoenolpyruvate (PEP) to oxaloacetate by fixing a carbon in the form of carbon dioxide or bicarbonate. Phosphoenolpyruvate carboxylase is encoded by the ppc gene in Escherichia coli, Corynebacterium and Bacillus, and the ppc1 in Saccharomyces cerevisiae. In the context of the present disclosure, ppc refers to the gene encoding phosphoenolpyruvate carboxylase, regardless of the strain encoding it.

[0032] In one embodiment of the present disclosure, phosphoenolpyruvate carboxylase can be, for example, overexpressed by placing the natural ppc gene under the control of a promoter stronger than the natural promoter, or by inserting a recombinant nucleic acid encoding phosphoenolpyruvate carboxylase into the cell. In a preferred embodiment, the promoter controlling citrate synthase expression is selected from Table 10.

[0033] In one embodiment, the nucleic acid encoding phosphoenolpyruvate carboxylase comprises or consists of the amino acid sequence of SEQ ID NO:2, or comprises or consists of an amino acid sequence that is at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identical to SEQ ID NO:2.

[0034] The recombinant nucleic acid encoding phosphoenolpyruvate carboxylase can be carried by a plasmid or integrated into the genome of the genetically modified cell. For large-scale production, in order to avoid selection pressure to maintain the plasmid in the cell, it is preferably integrated into the genome.

[0035] Isocitrate lyase regulator family (iclR)

[0036] The isocitrate lyase regulatory factor family or IclR family is well known in microorganisms, such as Gram-positive bacteria, α-, β- and γ-proteobacteria and archaea, often with IclR's name different (Molina-Henares et al., 2006FEMS Microbiol Rev 30: 157-186), but also exists in some fungi and plants. In Escherichia coli, IclR is a DNA binding transcriptional regulator that regulates the gene expression of the aceBAK operon encoding isocitrate lyase (aceB), malate synthase (aceA) and isocitrate dehydrogenase kinase / phosphorylase (aceK) in the glyoxylate bypass. IclR inactivation activates the glyoxylate bypass pathway. In the context of the present disclosure, the term isocitrate lyase regulatory factor or iclR is meant to include members of the isocitrate lyase regulatory factor family, and is not just Escherichia coli IclR. IclR family members are well characterized between different species and can be easily identified by those skilled in the art. In E. coli, an example of an IclR protein is NCBI accession number AAC76988.2.

[0037] In the context of the present disclosure, the function of the natural isocitrate lyase regulatory factor family member has been reduced or completely eliminated. The function can be lost or eliminated by deleting the iclR gene or making it dysfunctional, for example, by introducing a nonsense mutation to produce a premature stop codon to inactivate the regulatory factor. Preferably, the iclR gene is deleted in the host cell. An exemplary iclR gene sequence is provided as SEQ ID NO:30. Deletion of functional homologs of SEQ ID NO:30 is encompassed by the present disclosure. Functional homologs may not have a high degree of sequence similarity to SEQ ID NO:30, but their inactivation does activate the glyoxylate bypass pathway ( Figure 1 In one embodiment, the iclR gene sequence to be deleted in the cell is at least 50% identical to SEQ ID NO:30, such as at least 60%, such as at least 70%, such as at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identical to SEQ ID NO:30.

[0038] Reduction of IclR function may be achieved by introducing one or more missense mutations in the IclR gene, which cause a change in the amino acid sequence, thereby reducing the ability of the regulatory factor to bind to the aceBAK operon. The function may also be reduced by reducing the expression level of the iclR gene, for example by replacing the native promoter with a weaker promoter or a promoter that is only induced under certain conditions. Preferably, the function or expression level of IclR is reduced by at least 25%, such as at least 50%, such as at least 75%, such as at least 85%, such as at least 90%.

[0039] Human Milk Oligosaccharides (HMO)

[0040] In the context of the present disclosure, the term "oligosaccharide" refers to a sugar polymer containing multiple monosaccharide units. In some embodiments, preferred oligosaccharides are sugar polymers composed of three, four, five or six monosaccharide units, i.e. trisaccharides, tetrasaccharides, pentasaccharides or hexasaccharides. Most preferred are trisaccharides or tetrasaccharides. Preferred oligosaccharides of the present disclosure are human milk oligosaccharides (HMOs).

[0041] The term "human milk oligosaccharide" or "HMO" in the present context refers to a complex carbohydrate present in human breast milk. HMO has a core structure comprising a lactose unit at the reducing end, which may be extended by one or more β-N-acetyl-lactosaminyl and / or one or more β-lactose-N-disaccharide units, and the core structure may be substituted by α-L-fucopyranosyl and / or α-N-acetyl-neuraminic acid (α-N-acetyl-neuraminyl) (sialic acid) moieties. The HMO structure is disclosed, for example, by Xi Chen in Advances in Carbohydrate Chemistry and Biochemistry, 2015, Vol. 72, Chapter 4.

[0042] In the context of this disclosure, lactose is not considered an HMO species.

[0043] HMOs can be non-acidic (or neutral) or acidic. Neutral HMOs have no sialic acid residues, and acidic HMOs have at least one sialic acid residue in their structure. Non-acidic (or neutral) HMOs can be fucosylated or non-fucosylated. Examples of such neutral non-fucosylated HMOs include lacto-N-triose 2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-neohexaose (LNnH), p-lacto-N-neohexaose (pLNnH), p-lacto-N-hexaose (pLNH), and lacto-N-hexaose (LNH). Examples of neutral fucosylated HMOs include 2'-fucosyllactose (2'-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-difucohexaose I (LNDFH-I), 3-fucosyllactose (3'-FL), difucosyllactose (DFL), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose I (LNDFH-I). Hexaose III (LNDFH-III), fucosyl-lacto-N-hexaose II (FLNH-II), lacto-N-fucopentaose V (LNFP-V), lacto-N-difucohexaose II (LNDFH-II), fucosyl-lacto-N-hexaose I (FLNH-I), fucosyl-p-lacto-N-hexaose I (FpLNH-I), fucosyl-p-lacto-N-neohexaose II (F-pLNnH II) and fucosyl-lacto-N-neohexaose (FLNnH). Examples of acidic HMOs include 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), 3-fucosyl-3'-sialyllactose (FSL), 3'-O-sialyllacto-N-tetraose a (LST a), fucosyl-LST a (FLST a), 6'-O-sialyllacto-N-tetraose b (LST b), fucosyl-LST b (FLST b), 6'-O-sialyllacto-N-neotetraose (LST c), fucosyl-LST c (FLST c), 3'-O-sialyllacto-N-neotetraose (LST d), fucosyl-LST d (FLST d). d), sialic acid-lacto-N-hexaose (SLNH), sialic acid-lacto-N-neohexose I (SLNH-I), sialic acid-lacto-N-neohexose II (SLNH-II) and disialyl-lacto-N-tetraose (DSLNT). For example, see Bych et al. 2019 Current Opinion in Biotechnology 56:130-137 for a review of HMO production.

[0044] In one or more preferred embodiments, the one or more HMOs produced are selected from the group consisting of: LNT-II, pLNnH, LNT and LNnT, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II, LNDFH-III, 2'FL, DFL, 3FL, LST-a, 3'SL, 6'SL, LST-b, LST-c, FSL, FLST-a, DSLNT, LNnH and LNH.

[0045] In one embodiment, the one or more HMOs produced by the methods and / or genetically engineered cells disclosed herein are HMOs comprising a LNT-II core, such as LNT and / or LNnT, pLNnH and / or LNFP-I. Preferably, the HMOs produced are LNT and / or LNnT.

[0046] In one embodiment, one or more HMOs produced by the methods and / or genetically engineered cells disclosed herein are fucosylated HMOs, such as 2'FL, 3FL, DFL, FSL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II, or LNDFH-III. Preferably, the HMO produced is fucosyllactose, such as 2'FL, 3FL, or DFL. Even more preferably, the HMO produced is 2'FL.

[0047] In one embodiment, one or more HMOs produced by the methods and / or genetically engineered cells disclosed herein are sialylated HMOs, such as 3'SL, 6'SL, LST-a, LST-b, LST-c, FSL, or DSLNT. Preferably, the HMO produced is sialyllactose, such as 3'SL or 6'SL.

[0048] Receptor oligosaccharide

[0049] The genetically modified cells according to the present disclosure comprise at least one recombinant nucleic acid sequence encoding a glycosyltransferase activity capable of transferring a glycosyl moiety from an activating sugar to a galactose, glucose or N-acetylglucosamine moiety in an acceptor oligosaccharide.

[0050] In the context of the present disclosure, an acceptor oligosaccharide is an oligosaccharide that can serve as a substrate for a glycosyltransferase that can transfer a glycosyl moiety from a glycosyl donor to the acceptor oligosaccharide. The glycosyl donor is preferably a nucleotide-activated sugar, as described in the "Glycosyltransferase" section. The acceptor oligosaccharide can be a precursor for the preparation of more complex HMOs (composed of 4 monosaccharides or more). Therefore, the acceptor oligosaccharide can also be referred to as a precursor molecule.

[0051] The acceptor oligosaccharide may be an intermediate product of the present fermentation process, the end product of a separate fermentation process employing a separate genetically modified cell, or may be an enzymatically or chemically produced molecule.

[0052] In the present context, the acceptor oligosaccharide for the glycosyltransferase may be, for example, lactose, lacto-N-triose II (LNT-II), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 2'-fucosyllactose (2'FL), 3-fucosyllactose (3FL), 3'-sialyllactose (3'SL) or 6'-sialyllactose (6'SL). In a preferred embodiment, the acceptor molecule is lactose and is supplied to a genetically modified cell capable of producing an HMO, which in turn may also serve as an acceptor molecule within the cell, e.g., LNT-II serves as an acceptor molecule / substrate for a β-1,3-glycosyltransferase to generate LNT, which in turn may serve as an acceptor molecule for a fucosyltransferase, generating, for example, LNFP-I.

[0053] Glycosyltransferase

[0054] The genetically modified cells according to the present disclosure comprise at least one recombinant nucleic acid sequence encoding at least one glycosyltransferase capable of transferring a glycosyl residue from a glycosyl donor to an acceptor oligosaccharide to synthesize a human milk oligosaccharide product. The nucleic acid sequence encoding one or more expressed glycosyltransferases may be integrated into the genome of the genetically engineered cell (via chromosomal integration), or alternatively, it may be contained in a plasmid and expressed as a plasmid vector, as described in the present disclosure.

[0055] The genetically modified cell according to the present disclosure may comprise at least two recombinant nucleic acid sequences encoding two different glycosyltransferases capable of transferring a glycosyl residue from a glycosyl donor to an acceptor oligosaccharide.

[0056] The one or more glycosyltransferases are preferably selected from enzymes having the activity of α-1,2-fucosyltransferase, α-1,3-fucosyltransferase, α-1,3 / 4-fucosyltransferase, α-1,4-fucosyltransferase α-2,3-sialyltransferase, α-2,6-sialyltransferase, β-1,3-N-acetylglucosaminetransferase, β-1,6-N-acetylglucosaminetransferase, β-1,3-galactosyltransferase and β-1,4-galactosyltransferase, as described in more detail below.

[0057] β-1,3-N-acetylglucosamine transferase

[0058] β-1,3-N-acetylglucosamine transferase is any protein with the ability to transfer N-acetylglucosamine of UDP-N-acetylglucosamine to lactose or another acceptor molecule in a β-1,3-linkage. Preferably, the β-1,3-N-acetylglucosamine transferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the β-1,3-galactosyltransferase is of heterologous origin. Non-limiting examples of β-1,3-N-acetylglucosamine transferase are given in Table 1. β-1,3-N-acetylglucosamine transferase variants may also be useful, preferably such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the β-1,3-N-acetylglucosamine transferases in Table 1.

[0059] Table 1. List of β-1,3-N-acetylglucosamine transferases

[0060]

[0061]

[0062] Heterologous β-1,6-N-acetylglucosamine transferase

[0063] Heterologous β-1,6-N-acetylglucosamine transferase is any protein with the ability to transfer the N-acetylglucosamine of UDP-N-acetylglucosamine to an acceptor molecule in a β-1,6-linked manner. The β-1,6-N-acetylglucosamine transferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the β-1,6-galactosyltransferase is of heterologous origin. An example of a β-1,6-N-acetylglucosamine transferase is Csp2 (NCBI accession number WP_22844786.1) or a variant thereof from Chryseobacterium sp. KBW03, which can, for example, produce LNH or LNnH.

[0064] β-1,3-galactosyltransferase

[0065] β-1,3-galactosyltransferase is any protein that has the ability to transfer the galactose of UDP-galactose to the N-acetylglucosamine moiety in a β-1,3-linkage to an acceptor molecule. Preferably, the β-1,3-galactosyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the β-1,3-galactosyltransferase is of heterologous origin. Non-limiting examples of β-1,3-galactosyltransferases are given in Table 2. β-1,3-galactosyltransferase variants may also be useful, preferably such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the β-1,3-galactosyltransferases in Table 2.

[0066] Table 2. List of β-1,3-glycosyltransferases

[0067]

[0068] β-1,4-galactosyltransferase

[0069] β-1,4-galactosyltransferase is any protein with the ability to transfer galactose of UDP-galactose to the N-acetylglucosamine portion. Preferably, the β-1,4-galactosyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the β-1,4-galactosyltransferase is of heterologous origin. Table 3 gives non-limiting examples of β-1,4-galactosyltransferases. β-1,4-galactosyltransferase variants may also be useful, preferably such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the β-1,4-galactosyltransferases in Table 3.

[0070] Table 3. List of β-1,4-galactosyltransferases

[0071] Protein name GenBankID source HMO Products GalT WP_001262061.1 Helicobacter pylori LqCy LqCy AAF42257.1 Neisseria meningitidis MC58 LqCy

[0072] α-1,2-fucosyltransferase

[0073] α-1,2-fucosyltransferase is a protein that has the ability to catalyze the transfer of fucose from a donor substrate (e.g., GDP-fucose) to an acceptor molecule in an α-1,2-linkage. Preferably, the α-1,2-fucosyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the α-1,2-fucosyltransferase is of heterologous origin. Table 4 gives non-limiting examples of α-1,2-fucosyltransferases. α-1,2-fucosyltransferase variants may also be useful, preferably, such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the α-1,2-fucosyltransferases in Table 4.

[0074] Table 4. List of α-1,2-fucosyltransferases

[0075]

[0076]

[0077] α-1,3-fucosyltransferase

[0078] α-1,3-fucosyltransferase refers to a glycosyltransferase that catalyzes the transfer of fucose from a donor substrate (e.g., GDP-fucose) to an acceptor molecule in an α-1,3-linkage. Preferably, the α-1,3-fucosyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the α-1,3-fucosyltransferase is of heterologous origin. Non-limiting examples of α-1,3-fucosyltransferases are given in Table 5. α-1,3-fucosyltransferase variants may also be useful, preferably, such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the α-1,3-fucosyltransferases in Table 5.

[0079] Table 5. List of α-1,3-fucosyltransferases

[0080]

[0081] α-1,3 / 4-fucosyltransferase

[0082] α-1,3 / 4-fucosyltransferase refers to a glycosyltransferase that catalyzes the transfer of fucose from a donor substrate (e.g., GDP-fucose) to an acceptor molecule in an α-1,3- or α1,4-linkage. Preferably, the α-1,3 / 4-fucosyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the α-1,3 / 4-fucosyltransferase is of heterologous origin. Non-limiting examples of α-1,3 / 4-fucosyltransferases are given in Table 6. α-1,3 / 4-fucosyltransferase variants may also be useful, preferably, such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the α-1,3 / 4-fucosyltransferases in Table 6.

[0083] Table 6. List of α-1,3 / 4-fucosyltransferases

[0084]

[0085] α-2,3-Sialyltransferase

[0086] α-2,3-sialyltransferase refers to a glycosyltransferase that catalyzes the transfer of sialic acid from a donor substrate (e.g., CMP-N-acetylneuraminic acid) to an acceptor molecule in an α-2,3-linked manner. Preferably, the α-2,3-sialyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the 2,3-sialyltransferase is of heterologous origin. Non-limiting examples of α-2,3-sialyltransferases are given in Table 7. α-2,3-sialyltransferase variants may also be useful, preferably such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the α-2,3-sialyltransferases in Table 7.

[0087] Table 7. List of α-2,3-sialyltransferases

[0088]

[0089]

[0090] α-2,6-Sialyltransferase

[0091] α-2,6-sialyltransferase refers to a glycosyltransferase that catalyzes the transfer of sialic acid from a donor substrate (e.g., CMP-N-acetylneuraminic acid) to an acceptor molecule in an α-2,6-linked manner. Preferably, the α-2,6-sialyltransferase used herein is not derived from a species of genetically engineered cells, i.e., the gene encoding the 2,6-sialyltransferase is of heterologous origin. Non-limiting examples of α-2,6-sialyltransferases are given in Table 8. α-2,6-sialyltransferase variants may also be useful, preferably such variants have at least 80%, such as at least 85%, such as at least 90%, such as at least 95% identity with one of the α-2,6-sialyltransferases in Table 8.

[0092] Table 8. List of α-2,6-sialyltransferases

[0093]

[0094] Glycosyl donor-nucleotide activated sugar pathway

[0095] When implementing the method of the present disclosure, it is preferred that a glycosylation reaction mediated by a glycosyltransferase in which activated sugar nucleotides are used as glycosyl donors occurs. Activated sugar nucleotides generally have phosphorylated glycosyl residues connected to nucleosides. Specific glycosyltransferases only accept specific sugar nucleotides. Therefore, it is preferred that the following activated sugar nucleotides participate in glycosyl transfer: glucose-UDP-GlcNAc, UDP-galactose, UDP-glucose, UDP-N-acetylglucosamine, UDP-N-acetylgalactosamine (GlcNAc) and CMP-N-acetylneuraminic acid. Genetically modified cells according to the present disclosure may include one or more pathways for producing nucleotide activated sugars selected from glucose-UDP-GlcNAc, GDP-fucose, UDP-galactose, UDP-glucose, UDP-N-acetylglucosamine, UDP-N-acetylgalactosamine and CMP-N-acetylneuraminic acid (CMP-Neu5Ac). Table 9 below is a non-limiting example of glycosyl donors and HMO products that can be used for production, and this list may not be exhaustive.

[0096] Table 9. Glycosyl donor HMO product list

[0097]

[0098] In one embodiment of the method, the genetically modified cell can produce the above-mentioned one or more activated sugar nucleotides by a de novo approach. In this regard, the activated sugar nucleotides are produced by cells under the action of enzymes participating in the de novo biosynthetic pathway of the corresponding sugar nucleotides, starting from simple carbon sources such as glycerol, sucrose, fructose or glucose, in a stepwise reaction sequence (a review of monosaccharide metabolism is shown in, for example, HH Freeze and AD Elbein: Chapter 4: Glycosylation precursors, in: Essentials of Glycobiology, 2nd edition (Eds. A. Varki et al.), Cold Spring Harbour Laboratory Press (2009))).

[0099] The enzymes involved in the de novo biosynthetic pathway of activated sugar nucleotides may be naturally present in the cell or may be introduced into the cell by genetic or recombinant DNA techniques, all of which is part of the general knowledge of the person skilled in the art.

[0100] In another embodiment, the genetically modified cells can utilize salvaged monosaccharides for sugar nucleotides. In the salvage pathway, monosaccharides from degraded oligosaccharides are phosphorylated by kinases and converted into nucleotide sugars by pyrophosphorylases. The enzymes involved in this process can be heterologous enzymes, or can be native enzymes of the host cell.

[0101] Colanic acid gene cluster

[0102] For the production of fucosylated HMOs, the colanic acid gene cluster is very important to ensure the presence of sufficient GDP-fucose. In Escherichia coli, GDP-fucose is an intermediate in the production of the extracellular polysaccharide colanic acid, which is the major oligosaccharide of the bacterial cell wall. In the context of the present disclosure, the colanic acid gene cluster encodes enzymes involved in the de novo synthesis of GDP-fucose, while one or several genes downstream of GDP-L-fucose, such as wcaJ, can be deleted to prevent the conversion of GDP-fucose to colanic acid. The colanic acid gene cluster responsible for GDP-fucose formation includes or consists of the following genes: gmd encoding the protein GDP-mannose-4,6-dehydratase, wcaG(fcl) encoding the protein GDP-L-fucose synthase, wcaH encoding the protein GDP-mannose mannosylhydrolase, wcaI encoding the colanic acid biosynthetic glycosyltransferase, manB encoding the protein phosphomannose mutase, and manC encoding the protein mannose-1-phosphate guanylyltransferase.

[0103] In one or more exemplary embodiments, the colanic acid gene cluster responsible for GDP-fucose formation can be expressed from its native genomic locus. Expression can be actively regulated to increase GDP-fucose formation. Expression can be regulated in the following ways: exchanging the native promoter with the target promoter and / or by expressing the gene cluster from another genomic locus outside the native genomic locus to increase the copy number of the colanic acid gene encoding the protein, or free expression of the colanic acid gene cluster or its specific gene.

[0104] With respect to the present disclosure, the term "native genomic locus" in relation to the colanic acid gene cluster refers to the original and natural location of the gene cluster in the genome of a genetically engineered cell.

[0105] The de novo GDP-fucose pathway genes responsible for the formation of GDP-fucose include or consist of the following genes:

[0106] i) manA, which encodes the protein mannose-6-phosphate isomerase (EC 5.3.1.8, UniProt accession number P00946), which promotes the interconversion of fructose 6-phosphate (F6P) and mannose-6-phosphate;

[0107] ii) manB, which encodes a protein phosphomannose mutase (EC 5.4.2.8, UniProt accession number P24175), which is involved in the biosynthesis of GDP-mannose by catalyzing the conversion of mannose-6-phosphate to mannose-1-phosphate;

[0108] iii) manC, which encodes the protein mannose-1-phosphate guanylyltransferase (EC:2.7.7.13, UniProt accession number P24174), which is involved in the biosynthesis of GDP-mannose by synthesizing GDP-mannose from GTP and α-D-mannose-1-phosphate;

[0109] iv) gmd, which encodes the protein GDP-mannose-4,6-dehydratase (UniProt accession number P0AC88), which catalyzes the conversion of GDP-mannose to GDP-4-dehydro-6-deoxy-D-mannose;

[0110] v) wcaG (fcl), which encodes the protein GDP-L-fucose synthase (EC 1.1.1.271, UniProt accession number P32055), which catalyzes the two-step NADP-dependent conversion of GDP-4-dehydro-6-deoxy-D-mannose to GDP-fucose.

[0111] Thus, preferably, when producing one or more fucosylated heterologous products, the genetically engineered cells overexpress the entire colanic acid gene cluster and / or one or more genes of the de novo GDP-fucose pathway selected from the group consisting of manA, manB, manC, gmd and wcaG.

[0112] Sialyl sugar nucleotide synthesis pathway

[0113] If the genetically modified cell is to produce a sialylated HMO, then the genetically modified cell includes sialic acid sugar nucleotide synthesis capability, ie, the genetically modified cell includes a biosynthetic pathway for making a sialic acid sugar nucleotide such as CMP-N-acetylneuraminic acid as a glycosyl donor for the sialyltransferase. For example, the genetically modified cell includes sialic acid synthesis capability by providing exogenous UDP-GlcNAc 2-epimerase (e.g., neuC of Campylobacter jejuni (GenBank AAK91727.1) or equivalent (e.g., (GenBank CAR04561.1)), Neu5Ac synthase (e.g., neuB of Campylobacter jejuni (GenBank AAK91726.1) or equivalent (e.g., Flavobacterium limnosediminis sialic acid synthase, GenBank WP_023580510.1), and / or CMP-Neu5Ac synthetase (e.g., neuA of Campylobacter jejuni (GenBank AAK91728.1) or equivalent (e.g., Vibrio brasiliensis CMP-sialic acid synthase, GenBank WP_006881452.1).

[0114] In addition, the genetically modified cells preferably have a defective sialic acid decomposition pathway. "Sialic acid decomposition pathway" refers to a series of reactions that are usually controlled and catalyzed by enzymes, resulting in the degradation of sialic acid. The exemplary sialic acid decomposition pathway described below is the Escherichia coli pathway. In this pathway, sialic acid (Neu5Ac; N-acetylneuraminic acid) is degraded by enzymes NanA (N-acetylneuraminic acid lyase) and NanK (N-acetylmannosamine kinase) and NanE (N-acetylmannosamine-6-phosphate epimerase), all of which are encoded by the nanATEK-yhcH operon and are suppressed by NanR (http: / / ecocyc.org / ECOLI). By introducing mutation in endogenous nanA (N-acetylneuraminic acid lyase) (for example GenBank accession number D00067.1 (GL216588)) and / or nanK (N-acetylmannosamine kinase) gene (for example GenBank accession number (amino acid) BAE77265.1 (GL85676015)), and / or nanE (N-acetylmannosamine-6-phosphate epimerase, G1:947745) (these genes are incorporated herein by reference), defective sialic acid catabolic pathway is produced in E. coli host. Alternatively, nanT (N-acetylneuraminic acid transporter) gene is also inactivated or mutated. Other intermediates of sialic acid metabolism include: (ManNAc-6-P) N-acetylmannosamine-6-phosphate; (GlcNAc-6-P) N-acetylglucosamine-6-phosphate; (GlcN-6-P) glucosamine-6-phosphate and (Fruc-6-P) fructose-6-phosphate. In some preferred embodiments, nanA is mutated. In other preferred embodiments, nanA and nanK are mutated, while nanE remains functional. In another preferred embodiment, nanA and nanE are mutated, while nanK is not mutated, inactivated or deleted. Mutations are one or more changes in the nucleic acid sequence encoding the gene product of nanA, nanK, nanE and / or nanT. For example, mutations can be 1, 2, up to 5, up to 10, up to 25, up to 50 or up to 100 changes in the nucleic acid sequence. For example, nanA, nanK, nanE and / or nanT genes are mutated by null mutation. Null mutations described herein include amino acid substitutions, additions, deletions or insertions, which either result in enzyme loss of function (i.e., reduced or no activity) or enzyme loss (i.e., no gene product). "Delete" refers to a coding region that is completely or partially removed so that no (functional) gene product is produced.Inactivation means that the coding sequence has been altered so that the resulting gene product is functionally inactive, or the activity of the encoded gene product is less than 100%, such as 90%, 80%, 70%, 60%, 50%, 40%, 30% or 20% of the native, naturally occurring, endogenous gene product. Therefore, in the present disclosure, it is preferred to inactivate the nanA, nanK, nanE and / or nanT genes.

[0115] HMO transporter

[0116] The term "HMO transporter" refers to a biomolecule, such as a protein, that facilitates the transport / export of HMOs synthesized by a host cell across a cell membrane, such as into a cell culture medium, or transport / import of HMOs from a cell culture medium into the cell cytosol.

[0117] Oligosaccharide products, such as HMOs produced by cells, can accumulate both within the cell and in the extracellular matrix. The product can be transported to the supernatant in a passive manner, i.e., it diffuses outward across the cell membrane. More complex HMO products may remain in the cell, which may ultimately impair cell growth, thereby affecting the possible total yield of a single fermentation product. Major facilitator superfamily transporters (MFS transporters) can facilitate HMO transport.

[0118] In this context, the term "MFS transporter" refers to a protein that facilitates the transport of oligosaccharides, preferably HMOs, across or through a cell membrane, preferably from the cell cytosol to the cell culture medium, of HMOs / oligosaccharides synthesized by the genetically engineered cells described herein. Additionally or alternatively, MFS transporters may also facilitate the efflux of molecules that are not considered to be HMOs or oligosaccharides, such as lactose, glucose, cellular metabolites and / or toxins. The specificity for the sugar moiety of the product to be secreted may be altered by mutations known in the art of recombinant DNA techniques.

[0119] Therefore, in one or more exemplary embodiments, the genetically engineered cells according to the methods described herein also include a gene product that serves as a major facilitator superfamily transporter. The gene product that serves as a major facilitator superfamily transporter can be encoded by a recombinant nucleic acid sequence expressed in the genetically engineered cells. The recombinant nucleic acid sequence encoding the major facilitator superfamily transporter can be integrated into the genome of the genetically engineered cells, or expressed using a plasmid.

[0120] In one or more exemplary embodiments, the MFS transporter is selected from the group consisting of Bad, Nec, YberC, Fred, Vag, and Marc.

[0121] In one or more exemplary embodiments, the genetically engineered cells of the present disclosure thus express a heterologous MFS transporter selected from the group consisting of Vag (GenBank Accession ID WP_048785139.1), Nec (GenBank Accession ID WP_092672081.1), Fred (GenBank Accession ID WP_087817556.1), Marc (GenBank Accession ID WP_060448169.1), YberC (GenBank Accession ID EEQ08298.1), Bad (GenBank Accession ID WP_017489914.1), and a functional homolog of any one of Vag, Nec, Fred, Marc, YberC, or Bad, the amino acid sequence of which has 70% identity to the amino acid sequence of any one of Vag, Nec, Fred, Marc, YberC, or Bad.

[0122] In some embodiments, the genetically modified cells of the present disclosure comprise a nucleic acid sequence encoding a putative MFS (major facilitator superfamily) transporter derived from Rosenbergiella nectarea bacteria. More specifically, the present disclosure relates to a genetically modified cell optimized to produce HMOs, comprising a recombinant nucleic acid encoding an MFS transporter having at least 80%, such as at least 85%, such as at least 90%, such as at least 95% or 100% sequence identity to an amino acid sequence having GenBank Accession ID WP_092672081.1 (nec). In addition, the MFS transporter having GenBank Accession ID WP_092672081.1 is further described in WO2021 / 148615.

[0123] Nec is expected to promote increased efflux of produced sialylated HMOs, such as 3'SL in the genetically engineered cells of the present disclosure.

[0124] In some embodiments, the genetically modified cells of the present disclosure comprise a nucleic acid sequence encoding a putative MFS (major facilitator superfamily) transporter derived from Yersinia frederiksenii and / or Yersinia bercovieri. More specifically, the present disclosure relates to a genetically modified cell optimized to produce HMOs, comprising a recombinant nucleic acid encoding an MFS transporter having at least 80%, such as at least 85%, such as at least 90%, such as at least 95% or 100% sequence identity to an amino acid sequence having GenBank Accession ID WP_08781756.1 (fred) or GenBank Accession No. EEQ08298 (YberC). The MFS transporter with GenBank Accession ID WP_08781756.1 is further described in WO2021 / 148620, and the MFS transporter with GenBank Accession ID EEQ08298 is further described in WO2021 / 148610.

[0125] In some embodiments, the genetically modified cells of the present disclosure comprise a nucleic acid sequence encoding a putative MFS (major facilitator superfamily) transporter derived from Serratia marcescens. More specifically, the present disclosure relates to a genetically modified cell optimized to produce HMOs, comprising a recombinant nucleic acid encoding an MFS transporter having at least 80%, such as at least 85%, such as at least 90%, such as at least 95% or 100% sequence identity to an amino acid sequence having GenBank Accession ID WP_060448169.1 (marc). An MFS transporter having GenBank Accession ID WP_087817556.1 is further described in WO2021 / 148614.

[0126] In some embodiments, the genetically modified cells of the present disclosure comprise a nucleic acid sequence encoding a putative MFS (major facilitator superfamily) transporter derived from Pantoea vagans. More specifically, the present disclosure relates to a genetically modified cell optimized to produce HMOs, comprising a recombinant nucleic acid encoding an MFS transporter having at least 80%, such as at least 85%, such as at least 90%, such as at least 95% or 100% sequence identity to an amino acid sequence having GenBank Accession ID WP_048785139.1 (vag). MFS transporters having GenBank Accession ID WP_048785139.1 are further described in WO2021 / 148611.

[0127] Genetically modified cells

[0128] In this context, the terms "genetically modified cells" and "genetically engineered cells" are used interchangeably. As used herein, "genetically modified cells" refer to host cells whose genetic material has been altered by human intervention using genetic engineering techniques, such as, but not limited to, transformation or transfection, such as with heterologous polynucleotide sequences, Crisper / Cas editing and / or random mutagenesis. In one embodiment, the genetically engineered cells have been transformed or transfected with a recombinant nucleic acid sequence.

[0129] In one aspect of the present disclosure, a genetically modified cell is capable of producing one or more human milk oligosaccharides (HMOs), wherein the cell comprises the following modifications: a) overexpression of citrate synthase (gltA), b) one or more heterologous nucleic acids encoding one or more glycosyltransferases, and c) at least one biosynthetic pathway for making activated sugar nucleotides that can serve as glycosyl donors for the glycosyltransferases of b).

[0130] In a further aspect of the present disclosure, a genetically modified cell is capable of producing one or more human milk oligosaccharides (HMOs), wherein the cell comprises the following modifications: a) overexpression of citrate synthase (gltA), and b) one or more heterologous nucleic acids encoding one or more glycosyltransferases, and c) at least one biosynthetic pathway for making activated sugar nucleotides that can serve as glycosyl donors for the glycosyltransferases of b), and d) at least one of the following modifications: i) overexpression of phosphoenolpyruvate carboxylase (ppc), and / or ii) reduced or complete loss of function of isocitrate lyase regulator (iclR).

[0131] In addition to the genetic modifications in the gltA gene and the ppc gene and / or the iclR gene of the present disclosure, further genetic modifications may be selected, for example, from the inclusion of glycosyltransferases and / or metabolic pathway engineering and MFS transporters, as described in the above sections, which a person skilled in the art will know how to combine into a genetically modified cell capable of producing one or more HMOs of interest.

[0132] Genetically modified cells described herein that contain more than one glycosyltransferase activity typically produce a mixture of two or more HMOs, whereas cells with a single glycosyltransferase activity typically produce one or, at most, two HMOs.

[0133] In one embodiment of the present disclosure, the genetically modified cell comprises a recombinant nucleic acid sequence encoding a citrate synthase comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity to SEQ ID NO: 1.

[0134] In one embodiment of the present disclosure, the recombinant nucleic acid sequence encoding citrate synthase comprises a native gltA gene in its native locus, which is controlled by a promoter that is stronger than the native promoter.

[0135] In another embodiment of the present disclosure, the recombinant nucleic acid encoding citrate synthase is inserted into the genome of the cell as an additional copy of the native gltA gene, either at the same locus or at a different locus of the genome, or as an episomal copy, e.g., on a plasmid. If the host cell does not contain a native gltA gene, the heterologous nucleic acid encoding citrate synthase is inserted into a suitable locus of the genome, or as an episomal copy, e.g., on a plasmid. In a preferred embodiment, the promoter controlling the expression of citrate synthase is selected from Table 10.

[0136] In a further embodiment of the present disclosure, the genetically modified cell comprises a recombinant nucleic acid sequence encoding a phosphoenolpyruvate carboxylase, wherein the phosphoenolpyruvate carboxylase comprises the amino acid sequence of SEQ ID NO:2, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity with SEQ ID NO:2, or consists of the same.

[0137] In one embodiment of the present disclosure, the recombinant nucleic acid sequence encoding phosphoenolpyruvate carboxylase comprises in its native locus a native ppc gene controlled by a promoter stronger than the native promoter.

[0138] In another embodiment of the present disclosure, the recombinant nucleic acid encoding phosphoenolpyruvate carboxylase is inserted into the genome of the cell as an extra copy of the natural ppc gene, which can be in the same locus or different loci of the genome, or as a free copy, such as on a plasmid. If the host cell does not contain the natural ppc gene, the heterologous nucleic acid encoding citrate synthase is inserted into the appropriate locus of the genome, or as a free copy, such as on a plasmid. In a preferred embodiment, the promoter controlling the expression of citrate synthase is selected from Table 10.

[0139] In one embodiment of the present disclosure, the genetically modified cell comprises, in addition to the modifications required for production of one or more HMOs of interest, a) a recombinant nucleic acid sequence encoding a citrate synthase comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity thereto, and b) a recombinant nucleic acid sequence encoding a phosphoenolpyruvate carboxylase comprising, or consisting of, the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity thereto.

[0140] In one embodiment of the present disclosure, the genetically modified cell comprises, in addition to the modifications required for production of one or more HMOs of interest, a) a recombinant nucleic acid sequence encoding a citrate synthase comprising or consisting of an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity thereto, and b) a deletion or loss of function of the iclR gene.

[0141] In one embodiment of the present disclosure, the genetically modified cell comprises, in addition to the modifications required for producing one or more HMOs of interest, a) a recombinant nucleic acid sequence encoding a citrate synthase comprising, or consisting of, an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity thereto, and b) a recombinant nucleic acid sequence encoding a phosphoenolpyruvate carboxylase comprising, or consisting of, an amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity thereto, and c) a functional deletion or loss of the iclR gene.

[0142] In one embodiment of the present disclosure, the genetically modified cell comprises, in addition to the modifications required for production of one or more HMOs of interest, a) a recombinant nucleic acid sequence encoding a phosphoenolpyruvate carboxylase comprising, or consisting of, the amino acid sequence of SEQ ID NO: 2, or an amino acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity thereto, and b) a deletion or loss of function of the iclR gene.

[0143] The genetically engineered cells are preferably microbial cells, such as prokaryotic cells or eukaryotic cells. Suitable microbial cells that can serve as host cells include bacterial cells, archaeal cells, algae cells and fungal cells.

[0144] In a preferred embodiment, the genetically engineered cell is a bacterial cell that naturally expresses a protein of the isocitrate lyase regulator family.

[0145] Host cells

[0146] The genetically engineered cells may be any cells useful for HMO production, including mammalian cell lines. Preferably, the host cell is a unicellular microorganism of eukaryotic or prokaryotic origin. Suitable microbial cells that can serve as host cells include yeast cells, bacterial cells, archaeal cells, algae cells, and fungal cells.

[0147] The genetically engineered cell (host cell) can be, for example, a bacterial or yeast cell. In a preferred embodiment, the genetically engineered cell is a bacterial cell.

[0148] Regarding bacterial host cells, there are no restrictions in principle; they can be true bacteria (Gram-positive or Gram-negative) or archaea, as long as they allow genetic manipulation to insert the gene of interest and can be cultured on a production scale. Preferably, the host cell has properties that allow cultivation to high cell densities. Non-limiting examples of bacterial host cells suitable for the recombinant industrial production of HMOs can be Escherichia coli, Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Campylobacter sp, Corynebacterium sp., Pantoea citrea, Pectobacterium carotovorum or Xanthomonas campestris. Bacillus bacteria, including Bacillus subtilis, Bacillus licheniformis, Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans, may also be used.Similarly, bacteria of the genera Lactobacillus and Lactococcus can be engineered using the methods described herein, including, but not limited to, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, and Lactococcus lactis. Streptococcus thermophiles, Streptomyces lividans and Proprionibacterium freudenreichii are also suitable bacterial species. Also included are strains engineered as described herein from Enterococcus (e.g., Enterococcus faecium and Enterococcus thermophiles), Bifidobacterium (e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum), Sporolactobacillus spp., Micromomosporas spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas (e.g., Pseudomonas fluorescens and Pseudomonas aeruginosa).

[0149] Non-limiting examples of fungal host cells suitable for recombinant industrial production of HMO products can be yeast cells, such as Komagata ella phaffii, Kluyveromyces lactis, Yarrowia lipolytica, Pichia pastoris and Saccaromyces cerevisiae, or filamentous fungi, such as Aspargillus sp., Fusarium sp. or Trichoderma sp., exemplary species being A. niger, A. nidulans, A. oryzae, F. solani, F. graminearum and T. reesei.

[0150] In one or more exemplary embodiments, the genetically engineered cell is selected from the group consisting of Yarrowia lipolytica, Pichia pastoris, and Saccharomyces cerevisiae.

[0151] In one or more exemplary embodiments, the genetically engineered cell is Pichia pastoris.

[0152] In one or more exemplary embodiments, the genetically engineered cell is selected from the group consisting of Escherichia sp., Bacillus sp., Lactobacillus sp., Corynebacterium sp., and Campylobacter sp.

[0153] In one or more exemplary embodiments, the genetically engineered cell is selected from Escherichia coli (E. coli), Corynebacterium glutamicum (C. glutamicum), Lactococcus lactis, Bacillus subtilis, and Streptomyces lividans.

[0154] In one or more exemplary embodiments, the genetically engineered cell is Bacillus subtilis.

[0155] In one or more exemplary embodiments, the genetically engineered cell is Corynebacterium glutamicum.

[0156] In one or more exemplary embodiments, the genetically engineered cell is Escherichia coli.

[0157] In one or more exemplary embodiments, the genetically engineered cells are derived from E. coli K-12 strain or E. coli DE3.

[0158] Recombinant nucleic acid sequence

[0159] In the present context, the terms "recombinant nucleic acid sequence", "recombinant gene / nucleic acid / nucleotide sequence / DNA encoding..." or "coding nucleic acid sequence" are used interchangeably and are intended to refer to an artificial nucleic acid sequence (i.e., produced in vitro using standard laboratory methods for making nucleic acid sequences) that comprises a set of consecutive, non-overlapping triplets (codons) that are transcribed into mRNA and translated into protein when under the control of appropriate control sequences (i.e., promoter sequences).

[0160] The boundaries of the coding sequence are usually determined by the ribosome binding site, transcription initiation codon (AUG, GUG or UUG) and translation termination codon (UAA, UGA or UAG) upstream of the open reading frame at the 5' end of the mRNA. The coding sequence may include, but is not limited to, genomic DNA, cDNA, synthetic and recombinant nucleic acid sequences.

[0161] The term "nucleic acid" includes RNA, DNA and cDNA molecules. It will be appreciated that due to the degeneracy of the genetic code, a large number of nucleic acid sequences can be generated that encode a given protein.

[0162] The recombinant nucleic acid sequence can be a coding DNA sequence, such as a gene, or a non-coding DNA sequence (eg, regulatory DNA, such as a promoter sequence or other non-coding regulatory sequences).

[0163] In addition, the recombinant nucleic acid sequence can be heterologous. As used herein, "heterologous" refers to a polypeptide, amino acid sequence, nucleic acid sequence or nucleotide sequence that is foreign to a cell or organism, i.e., a polypeptide, amino acid sequence, nucleic acid molecule or nucleotide sequence that is not naturally present in the cell or organism.

[0164] The present disclosure also relates to nucleic acid constructs comprising a coding nucleic acid sequence, i.e., a recombinant DNA sequence of a gene of interest, such as citrate synthase and / or phosphoenolpyruvate carboxylase, and a non-coding regulatory DNA sequence, such as a promoter DNA sequence, e.g., a recombinant promoter sequence derived from a promoter sequence of the lac operon or the glp operon, or a promoter sequence derived from another genomic promoter DNA sequence, or a synthetic promoter sequence, wherein the coding and promoter sequences are operably linked.

[0165] The term "operably linked" refers to a functional relationship between two or more nucleic acid (e.g., DNA) segments. It refers to the functional relationship of a transcriptional regulatory sequence to a transcribed sequence. For example, a promoter sequence is operably linked to a coding sequence if the promoter sequence stimulates or regulates transcription of the coding sequence in a suitable host cell or other expression system.

[0166] Typically, promoter sequences operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, ie, they are cis-acting.

[0167] In one exemplary embodiment, the nucleic acid construct of the present disclosure may be part of a vector DNA, in another embodiment, the construct is an expression cassette / cassette that is integrated into the host cell genome.

[0168] Therefore, the term "nucleic acid construct" refers to an artificially constructed nucleic acid fragment, particularly a DNA fragment, which is intended to be inserted into a target cell, such as a bacterial cell, to modify the expression of a genomic gene or the expression of a gene / coding DNA sequence that may be contained in the construct. Therefore, in an embodiment, the present disclosure relates to a nucleic acid construct comprising a recombinant nucleic acid sequence encoding citrate synthase and / or phosphoenolpyruvate carboxylase, wherein the recombinant nucleic acid sequence is selected from a nucleic acid sequence encoding a protein of SEQ ID NO: 1 and / or SEQ ID NO: 2 or a functional variant thereof.

[0169] One embodiment of the present disclosure is a nucleic acid construct comprising a recombinant nucleic acid sequence encoding a citrate synthase, wherein the recombinant nucleic acid sequence comprises or consists of a nucleic acid sequence of SEQ ID NO: 3 or a nucleic acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity to SEQ ID NO: 3. Preferably, the sequence encoding the citrate synthase is under the control of a promoter sequence selected from a promoter sequence having a nucleic acid sequence as shown in Table 10.

[0170] Another embodiment of the present disclosure is a nucleic acid construct comprising a recombinant nucleic acid sequence encoding phosphoenolpyruvate carboxylase, wherein the recombinant nucleic acid sequence comprises or consists of a nucleic acid sequence of SEQ ID NO: 4 or a nucleic acid sequence having at least 80%, such as at least 85%, such as at least 90%, such as at least 95%, or such as at least 99% identity to SEQ ID NO: 4. Preferably, the sequence encoding phosphoenolpyruvate carboxylase is under the control of a promoter sequence selected from a promoter sequence having a nucleic acid sequence as shown in Table 10.

[0171] Table 10 - Selected promoter sequences

[0172]

[0173] *Promoter activity was assessed in the LacZ assay described below, with the PglpF promoter as a positive reference in the same assay. To compare different assays, activity relative to the PglpF promoter was calculated, and the range indicates results from multiple assays.

[0174] The promoter may be of heterologous origin, be native to the genetically modified cell, or may be a recombinant promoter combining heterologous and / or native elements.

[0175] One approach to increasing product yields may be to modulate the production of a desired enzyme activity for producing the product, such as a glycosyltransferase or an enzyme involved in a glycosyl donor biosynthetic pathway.

[0176] Increasing the promoter strength that drives the desired enzyme expression may be a way to achieve this goal. The strength of the promoter can be evaluated using the lacZ enzyme assay, in which the β-galactosidase activity is measured as described above (see Miller JH Experiments in molecular genetics, Cold spring Harbor Laboratory Press, NY, 1972). In short, cells are diluted in Z buffer and infiltrated with sodium dodecyl sulfate (0.1%) and chloroform. The LacZ assay is performed at 30°C. The sample is preheated, the assay is started by adding 200 μl of o-nitro-phenyl-β-galactosidase (4 mg / ml), and 500 μl of 1M Na2CO3 is added when the sample turns slightly yellow to stop the assay. The release of o-nitrophenol is then determined as the change in optical density at 420 nm. The specific activity is reported in Miller units (MU) [A420 / (min*ml*A600)]. Regulatory elements with an activity above 10,000 MU are considered strong, those with an activity below 3000 MU are considered weak, and those in between have intermediate strength. An example of a strong regulatory element is the PglpF promoter, which has an activity of approximately 14,000 MU, and an example of a weak promoter is Plac, which has an activity of approximately 2300 MU when induced with IPTG.

[0177] In an embodiment, the expression of the nucleic acid sequence of the present disclosure is under the control of the following promoters: PglpF (SEQ ID NO: 17) or Plac (SEQ ID NO: 26) or PmglB_UTR70 (SEQ ID NO: 14) or PglpA_70UTR (SEQ ID NO: 15) or PglpT_70UTR (SEQ ID NO: 16) or Pcon3_70UTR (SEQ ID NO: 29), or variants of these promoters, as shown in Table 10, in particular PglpF variants of SEQ ID NO: 12, 18, 19, 20, 22, 23 or 24 or Plac variants of SEQ ID NO: 8 or PmglB_70UTR variants of SEQ ID NO: 5, 6, 7, 9, 10, 11, 13 or 21. Further suitable variants of the PglpF, PglpA_70UTR, PglpT_70UTR and PmglB_70UTR promoter sequences are described in WO2019 / 123324 and WO2020 / 255054, respectively (incorporated herein by reference).

[0178] The target nucleic acid construct contained in the construct (expression cassette) can be integrated into the bacterial genome by conventional methods, for example, by using a linear cassette containing flanking sequences homologous to specific sites on the chromosome, such as the attTn7 site (Waddell CS and Craig N.L., Genes Dev. (1988) Feb; 2(2): 137-49); methods for genomic integration of nucleic acid sequences, wherein recombination is mediated by the Red recombinase function of bacteriophage λ or the RecE / RecT recombinase function of the Rac prophage (Murphy, J Bacteriol. (1998); 180(8): 2063-7; Zhang et al., Nature Genetics (1998) 20: 123-128; Muyrers et al., EMBO Genetics (1998) 21: 123-128; Muyrers et al., EMBO Genetics (1998) 23: 137-139; Muyrers et al., EMBO Genetics (1998) 24: 137-139; Muyrers et al., EMBO Genetics (1998) 25: 137-139; Muyrers et al., EMBO Genetics (1998) 26: 143-147 ... Rep. (2000) 1(3):239-243); Red / ET recombination-based methods (Wenzel et al., ChemBiol. (2005), 12(3):349-56; Vetcher et al., Appl EnvironMicrobiol. (2005); 71(4):1829-35); or positive clones, i.e., clones carrying the expression cassette, can be selected, for example, by loss or gain of marker gene or gene function.

[0179] In one or more exemplary embodiments, the present disclosure relates to a nucleic acid construct comprising one or more recombinant nucleic acid sequences shown in SEQ ID NO: 3 or 4 [nucleic acids encoding gltA or ppc, respectively] and a promoter sequence selected from Table 10 at the 5' end of SEQ ID NO: 30 or 4.

[0180] In a specific embodiment, SEQ ID NO:3 and / or 4 are under the control of the Pcon3_70UTR promoter (SEQ ID NO:29).

[0181] In a specific embodiment, SEQ ID NO: 3 and / or 4 are under the control of the PglpF promoter (SEQ ID NO: 17).

[0182] In particular, the present disclosure relates to one or more recombinant nucleic acid sequences and / or functional homologs thereof, said functional homologs having a sequence having at least 70% identity, such as at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 98% identity, or 100% identity to SEQ ID NO:3 or 4 [nucleic acids encoding gltA or ppc, respectively].

[0183] Sequence identity

[0184] The term "sequence identity" as used herein describes the correlation between two amino acid sequences or between two nucleotide sequences based on their paired comparisons, i.e., a candidate sequence (e.g., a sequence of the present disclosure) and a reference sequence (e.g., a prior art sequence). For purposes of the present disclosure, the sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mo / . Biol. 48: 443-453), which is implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 5.0.0 or higher (available at https: / / www.ebi.ac.uk / Tools / psa / emboss needle / ). The parameters used are gap open penalty (gap open penalty) 10, gap extension penalty (gap extension penalty) 0.5, and EBLOSUM62 (EMBOSS version of 30BLOSUM62) substitution matrix. The output of Needle (obtained using-nobrief option) labeled as "longest identity" is used as percentage identity, and is calculated as follows: (identical residue x 100) / (total number of gaps in comparison length-comparison).

[0185] For the purpose of the present disclosure, the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, the same) implemented in the Needle program (EMBOSS:The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet.16:276-277) of the EMBOSS package is used to determine the sequence identity between two nucleotide sequences, 10 preferred versions 5.0.0 or higher versions. The parameter used is gap open penalty (gap open penalty) 10, gap extension penalty (gap extension penalty) 0.5, and DNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output (using-nobrief option to obtain) of the Needle marked as "longest identity" is used as identity percentage, and is calculated as follows: (identical deoxyribonucleotide x 100) / (total number of spaces in comparison length-comparison).

[0186] Functional homologs

[0187] Functional homologues or functional variants of protein / nucleic acid sequences as described herein are protein / nucleic acid sequences with altered genetic codes that retain their original functions. Functional homologues can be obtained by mutagenesis, or can be naturally occurring variants from the same or other species. Compared to the function of the protein / nucleic acid sequence, a functional homologue should have at least 50%, for example at least 60%, 70%, 80%, 90% or 100% residual function / activity.

[0188] Functional homologs with reduced remaining function / activity will be considered as variants with reduced function. Functional homologs or variants with reduced function can be obtained, for example, by introducing one or more missense mutations in the coding gene, which result in changes in the amino acid sequence that reduce the function of the expressed polypeptide. Variants that retain less than 5% function / activity of the encoded polypeptide are considered to have completely lost function. The introduction of nonsense mutations results in premature stop codons, which renders the transcribed polypeptide dysfunctional and can be used to generate host cells with completely lost function. Complete loss of function can also be obtained by deleting the gene encoding the polypeptide of interest.

[0189] In one embodiment of the present disclosure, the function of the host cell isocitrate lyase regulator (IclR) is reduced or completely lost. In a preferred embodiment, the iclR gene has been deleted from the host cell.

[0190] Functional homologues of any of the disclosed amino acid or nucleic acid sequences may also have higher functions. Functional homologues of any of the proteins shown in Tables 1, 2, 3, 4, 5, 6, 7, 8 and 9, or recombinant nucleic acids encoding any of the proteins in these tables, should ideally be able to participate in the production of one or more HMOs. Functional homologues of SEQ ID NO: 1 or SEQ ID NO: 2 with higher functions are also included in the present disclosure, as the higher functions may achieve the same effects as the overexpression described herein.

[0191] Use of genetically modified cells

[0192] The present disclosure also relates to any commercial use of the genetically modified cells or nucleic acid constructs disclosed herein, such as, but not limited to, methods for producing one or more human milk oligosaccharides (HMOs).

[0193] In an embodiment of the present disclosure, the genetically modified cells and / or nucleic acid constructs according to the present disclosure are used to produce HMOs. Preferably, the genetically modified cells are used to produce one or more HMOs on a large scale. In one embodiment of the present disclosure, the large-scale fermentation reaches a final fermentation volume of 1,000 L or more, such as 10,000 L or more, such as 50,000 L or more, preferably 100,000 L or more.

[0194] Specifically, the use of the genetically modified cells of the present disclosure enables fermentations that produce significantly less acetic acid or ethanol during fermentation, particularly during the non-carbon-limited growth phase of the fermentation (e.g., the batch phase in a fed-batch fermentation), compared to the same HMO production cells without a) overexpression of citrate synthase (gltA), or b) overexpression of citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc), or c) overexpression of citrate synthase (gltA) with reduced or complete loss of function of the isocitrate lyase regulatory factor (iclR), or d) overexpression of citrate enzyme (gltA) and phosphoenolpyruvate carboxylase (ppc) with reduced or complete loss of function of the isocitrate lyase regulatory factor (iclR).

[0195] Preferably, the acetate level is reduced by at least 30%, such as at least 40%, such as at least 50%, such as at least 60%, such as at least 70%, compared to cells without the modification of the present disclosure. If the fermentation is a batch fermentation, the acetate level is measured when the carbon source (sugar) is exhausted. If the fermentation is a batch feed or continuous batch feed fermentation, it is ideal to measure the acetate level when the carbon source is exhausted, which is usually when the feeding begins. Carbon source exhaustion in the fermentation can be determined by direct measurement (HPLC, sticks, etc.) or indications from online fermentation data, such as an increase in dissolved oxygen (DO) or a decrease in rpm, or both, usually in combination with an increase in pH. Alternatively, a decrease in CER (CO2 release rate) or OUR (oxygen absorption rate) can be used as a measurement of carbon source exhaustion. Preferably, the acetate level is measured according to the stress test described in the method section. For host cells whose overflow metabolism results in ethanol formation instead of or in addition to acetate formation, which is typical of yeast cells, the genetically modified cells of the disclosure produce less ethanol (and acetate) than cells without the modifications of the disclosure.

[0196] In further embodiments of the present disclosure, the genetically modified cells of the present disclosure are used to improve the robustness of the cells in large-scale fermentations, particularly when subjected to high gradients of the carbon source used to feed the cells. Ideally, when the genetically modified cells of the present disclosure encounter high carbon source gradients or large pulses of carbon source (such as glucose and / or sucrose added to the fermentation), the formation of HMO products is not significantly affected.

[0197] For purposes of this disclosure, a carbon source gradient is a localized region in a fermentor where the concentration of the carbon source used to feed the cells is higher than the average concentration for the entire fermentor. Carbon source gradients are ubiquitous in large-scale fermentations, particularly in the region around the feed port, but they may also occur in other regions of the fermentor due to insufficient mixing. Specifically, a carbon source gradient may be a localized region where the molar concentration of the carbon source within the fermentor is higher than the Ks for the bacterial sugar uptake system, which will roughly translate to the onset of overflow metabolism. Preferably, the carbon source gradient is more than 2 times, such as 5 times, such as 10 times, the Ks, which is where cellular acetate accumulation begins to become severe.

[0198] In the context of the present disclosure, Ks refers to substrate affinity, i.e. the substrate concentration at which cells grow at half the maximum specific growth rate in the Monod model, which describes the relationship between growth rate and substrate concentration in a microbial population grown under a single limiting carbon source. For example, the Escherichia coli growth behavior using the Monod model has been described in Wick et al. 2002, Microbiology 148, 2889-2902 and Senn et al. 1994 Biochimica et Biophysica Acta 1201, 424-436.

[0199] In a preferred embodiment, when exposed to such carbon source gradients, the modified organisms of the present disclosure will produce less acetate or ethanol than unmodified cells. The amount of acetate or ethanol formed when cells are exposed to carbon source gradients will also depend on the time that cells spend in the gradient. Therefore, when assessing the reduction of acetate or ethanol formation, in addition to the concentration of the carbon source in the gradient, the time that cells spend in this gradient can also be considered. Preferably, when reaching the acetate or ethanol reduction level achieved by modifying cells, cells spend at least 10 seconds, such as at least 15 seconds, such as at least 20 seconds, such as at least 30 seconds, in the carbon source gradient. The time spent in the carbon source gradient depends on several factors, such as the stirring speed in the bioreactor, the position where the carbon source inlet is placed in the reactor, the amount and concentration of the carbon source feed in the reactor. In the context of the present disclosure, the carbon source gradient can be simulated on a smaller scale by applying a glucose pulse, as described in the pressure test in the method sections.

[0200] Method for producing human milk oligosaccharides (HMO)

[0201] The present disclosure also relates to a method of producing human milk oligosaccharides (HMOs), the method comprising culturing a genetically modified cell according to the present disclosure in a suitable culture medium.

[0202] The method comprises culturing a genetically modified cell that produces an HMO, and further comprises culturing the genetically modified cell in the presence of an energy source (carbon source) selected from glucose, sucrose, fructose, xylose and glycerol. Preferably, the carbon source is a carbon source that results in overflow metabolism when present in excess during fermentation. Preferably, the carbon source is glucose or sucrose, including hydrolyzed sucrose.

[0203] In a preferred embodiment, the cultivation is a fed-batch fermentation or a continuous fed-batch (feed and drain fermentation), wherein the carbon source is continuously fed to the fermentation broth during the fermentation.

[0204] In one aspect, the method of the present disclosure further comprises providing an acceptor sugar as a substrate for HMO formation, the acceptor sugar comprising at least two monosaccharide units, which is exogenously added to the culture medium and / or produced by a separate microbial fermentation. In a preferred embodiment, the substrate for HMO formation is lactose, which is fed to the culture during fermentation of the genetically engineered cells. For example, alternative acceptor sugars can be LNT-II, 2'FL, 3FL, 3'SL, 6'SL, LNnT and LNT, which can be exogenously added to the culture medium and / or produced by a separate microbial fermentation. If the fermentation is a fed batch or continuous fed batch fermentation, the acceptor sugar is preferably provided at the end of the batch stage.

[0205] Cultivation or fermentation (used interchangeably herein) in a controlled bioreactor generally includes (a) a first phase of exponential cell growth in a medium ensured by a carbon source, and (b) a second phase of cell growth in a medium operated under carbon limitation, wherein the carbon source is continuously added along with an acceptor oligosaccharide (such as lactose) to allow the formation of HMO products during this phase. Carbon (sugar) limitation refers to the phase in the fermentation where the growth rate is dynamically controlled by the concentration of the carbon source (sugar) in the culture broth, which is determined by the rate at which carbon is added to the fermentor (sugar feed rate).

[0206] With respect to the present disclosure, the term "carbon source excess" is understood as an amount of carbon source that results in a growth rate between 50% of the maximum growth rate and the maximum growth rate. When cells are grown in excess of a carbon source, the overflow metabolism of the cells is activated, and the cells will begin to produce acetate and / or ethanol. In a non-limiting example, when cells are grown between 28°C and 33°C, the carbon source excess is above 0.05 mM carbon source, such as above 0.75 mM, preferably above 1 mM carbon source.

[0207] One embodiment of the present disclosure is a method for producing human milk oligosaccharides (HMOs), comprising the steps of: a) fermenting a genetically modified cell according to the present disclosure in at least 1,000 L of a cell culture medium comprising an initial amount of a carbon source (batch phase); and b) once the carbon source in step a) is consumed, starting to feed the fermentation broth with a carbon source and an acceptor oligosaccharide (feed phase) to produce a fermentation broth comprising an HMO-producing microorganism and one or more HMO products, wherein in the batch phase of the fermentation, at any time point during the batch phase of the fermentation, the acetate level is less than 5.0 g / L, preferably less than 4.0 g / L, preferably less than 3.5 g / L, more preferably less than 3.0 g / L, most preferably less than 2.5 g / L, and wherein in the feed phase, at any time point during the feed phase of the fermentation, the acetate level is less than 500 mg / L, preferably less than 400 mg / L, more preferably less than 300 mg / L, and most preferably less than 250 mg / L. Preferably, the HMO product is removed from the fermentation at the end of the fermentation.

[0208] At the end of the culture / fermentation, the HMO product may accumulate both within the cells and in the extracellular matrix, from which the HMO product may be extracted as described in the "Extraction / Harvesting" section.

[0209] The terms "manufacturing" or "manufacturing scale" or "large-scale production" or "large-scale fermentation" are used interchangeably and, in the meaning of the present disclosure, define fermentations with a minimum volume of 1,000 L, such as 10,000 L, 50,000 L, 100,000 L, 200,000 L, 300,000 L of culture broth. In general, "manufacturing scale" processes are defined as being able to process large volumes of the HMO product of interest, e.g., in the case of therapeutic compounds or compositions, to meet the needs of toxicity testing, clinical trials, and market supply. In addition to the large volumes, unlike simple laboratory scale methods such as shake flask cultures, manufacturing scale methods are characterized by technological systems using bioreactors (fermenters) equipped with means for stirring, aeration, nutrient feeding, monitoring and control of process parameters (pH, temperature, dissolved oxygen tension, back pressure, etc.). To a large extent, the behavior of the expression system in laboratory scale methods, such as shake flasks, benchtop bioreactors, or the deep well format described in the examples of the present disclosure, does allow predictions of the behavior of the system in the complex environment of the bioreactor.

[0210] Regarding the suitable cell culture medium used in the fermentation process, there are no restrictions. The culture medium can be semi-defined, i.e. containing complex culture medium compounds (e.g. yeast extract, soy peptone, casamino acids, etc.), or it can be chemically defined without any complex compounds. The carbon source can be selected from glucose, sucrose, fructose, xylose and glycerol. In one or more exemplary embodiments, the culture medium is supplemented with one or more energy sources and carbon sources selected from the group containing glycerol, sucrose and glucose. Preferably, the carbon source is glucose or sucrose.

[0211] In one or more exemplary embodiments, the culture medium contains sucrose as the sole carbon and energy source. In one or more exemplary embodiments, the genetically engineered cell comprises one or more heterologous nucleic acid sequences encoding one or more heterologous polypeptides capable of utilizing sucrose as the sole carbon and energy source of the genetically engineered cell, such as a PTS-dependent sucrose utilization system, which further comprises the scrYA and scrBR operons described in WO2015 / 197082.

[0212] Following performance of the methods of the present disclosure, the produced HMOs may be collected from the cell culture or fermentation broth in a conventional manner.

[0213] Extraction / Harvesting

[0214] Extracting human milk oligosaccharides (HMO) from culture medium and / or genetically modified cells. In the context of the present disclosure, the term "extracting" is used interchangeably with the term "harvesting". In this context, both "extracting" and "harvesting" are related to collecting the produced HMO from the culture / liquid after the fermentation is terminated. In one or more exemplary embodiments, it may include collecting the HMO contained in both the biomass (i.e., host cells) and the culture medium, i.e., before / without separation of the fermentation broth from the biomass. In other embodiments, the produced HMO can be collected separately from the biomass and the fermentation broth, i.e., after / subsequently separation of the biomass from the culture medium (i.e., the fermentation broth).

[0215] The separation of cells from the culture medium can be carried out by any of the methods known to those skilled in the art, such as any suitable type of centrifugation or filtration. The separation of cells from the culture medium can be carried out immediately after harvesting the fermentation broth, or can be carried out at a later stage after the fermentation broth is stored under appropriate conditions. Recovering the produced HMO from the remaining biomass (or total fermentation broth) includes extracting the HMO from the biomass (i.e., the production cells). In particular, when the produced HMO is not easily expelled from the cells, the HMO can be obtained by perforating the cells to allow the HMO to be released from the cells without necessarily completely destroying the cells. The advantage of this is that proteins, DNA and other molecules remain in the cells, thereby simplifying the downstream purification of the HMO.

[0216] After recovery from fermentation, HMOs can be used for further processing and purification.

[0217] HMOs can be purified according to methods known in the art, for example, such as described in WO2017 / 182965 or WO2017 / 152918, wherein the latter describes the purification of sialylated HMOs. The purified HMOs can be used as nutraceuticals, pharmaceuticals or for any other purpose, such as for research.

[0218] Manufacturing products

[0219] Depending on the use of the genetically engineered cell or nucleic acid construct, the term "manufacturing product" refers to one or more HMOs intended as one or more product HMOs. The various products are as described above.

[0220] The manufactured product may be a powder, composition, suspension or gel comprising one or more HMOs.

[0221] sequence

[0222] This application contains a Sequence Listing in both text and electronic formats, which is hereby incorporated by reference.

[0223] A summary of the SEQ ID NOs used in this application is shown in the table.

[0224] Summary of sequences listed in the application

[0225] name Comment SEQ ID NO gltA Citrate synthase protein sequence 1 ppc Phosphoenolpyruvate carboxylase protein sequence 2 gltA Citrate synthase DNA coding sequence 3 ppc Phosphoenolpyruvate carboxylase DNA coding sequence 4 Promoter sequence The promoter sequences listed in Table 10 5-28 Pcon3_70UTR Promoter sequence 29 iC Isocitrate lyase regulator family DNA sequences 30

[0226] project

[0227] The following is a list of preferred projects for this application

[0228] 1. A genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs), wherein the cell comprises the following modifications:

[0229] a) overexpression of citrate synthase (gltA), and

[0230] b) one or more heterologous nucleic acids encoding one or more glycosyltransferases, and

[0231] c) at least one biosynthetic pathway for producing an activated sugar nucleotide capable of serving as a glycosyl donor for the glycosyltransferase of b).

[0232] 2. The genetically modified cell according to any one of item 1, wherein the overexpression of citrate synthase is achieved by one or more of the following modifications:

[0233] a) placing the native gltA gene under the control of a stronger promoter than the native promoter, or

[0234] b) inserting into the cell a nucleic acid encoding a citrate synthase comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity with SEQ ID NO: 1.

[0235] 3. The genetically modified cell according to any one of items 1 or 2, wherein the cell further comprises at least one of the following modifications:

[0236] i. Overexpression of phosphoenolpyruvate carboxylase (ppc), and / or

[0237] ii. The function of isocitrate lyase regulator (iclR) is reduced or completely lost.

[0238] 4. The genetically modified cell according to item 3, wherein the overexpression of phosphoenolpyruvate carboxylase is achieved by one or more of the following modifications:

[0239] a) placing the native ppc gene under the control of a promoter that is stronger than the native promoter, or

[0240] b) inserting into the cell a nucleic acid encoding a phosphoenolpyruvate carboxylase, wherein the phosphoenolpyruvate carboxylase comprises or consists of the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity with SEQ ID NO: 2.

[0241] 5. The genetically modified cell according to item 3 or 4, wherein the gene encoding the isocitrate lyase regulator (iclR) is deleted or becomes dysfunctional.

[0242] 6. A genetically modified cell according to any of the preceding items, wherein overexpression of the gltA and / or ppc gene is controlled by a promoter selected from a promoter sequence having a nucleic acid sequence as shown in Table 10, preferably selected from a promoter sequence selected from SEQ ID NO: 17 (PglpF) or SEQ ID NO: 26 (Plac) or SEQ ID NO: 14 (PmglB_UTR70) or SEQ ID NO: 15 (PglpA_70UTR) or SEQ ID NO: 16 (PglpT_70UTR) or SEQ ID NO: 29 (Pcon3_70UTR), or variants thereof.

[0243] 7. The genetically modified cell according to any one of the preceding items, wherein a nucleic acid encoding citrate synthase (gltA) and / or phosphoenolpyruvate carboxylase (ppc) is inserted into the genome of the genetically modified cell.

[0244] 8. A genetically modified cell according to any of the preceding items, wherein the one or more glycosyltransferases are selected from enzymes having the activity of α-1,2-fucosyltransferase, α-1,3-fucosyltransferase, α-1,3 / 4-fucosyltransferase, α-1,4-fucosyltransferase α-2,3-sialyltransferase, α-2,6-sialyltransferase, β-1,3-N-acetylglucosaminetransferase, β-1,6-N-acetylglucosaminetransferase, β-1,3-galactosyltransferase and β-1,4-galactosyltransferase.

[0245] 9. The genetically modified cell according to item 8, wherein the one or more glycosyltransferases are selected from α-1,2-fucosyltransferases, α-1,3-fucosyltransferases and / or α-1,3 / 4-fucosyltransferases of Table 4, 5 or 6.

[0246] 10. The genetically modified cell according to any one of the preceding items, wherein the glycosyltransferase is a fucosyltransferase and at least one of the genes necessary for de novo synthesis of GDP-fucose in the biosynthetic pathway is overexpressed.

[0247] 11. The genetically modified cell according to item 10, wherein the genes manB, manC, gmd and wcaG of the de novo GDP-fucose pathway are all overexpressed.

[0248] 12. The genetically modified cell according to item 10 or 11, wherein manA is overexpressed.

[0249] 13. The genetically modified cell of any one of items 1 to 8 or 10 to 12, wherein the one or more HMOs are selected from the group consisting of: LNT, LNnT, LNH, LNnH, pLNH, pLNnH, 2'FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II, LNDFH-III, F-pLNH, pLNnH, FLSTa, FLSTb, FLSTc, FLSTd, FSL, 3'SL, 6'SL, LSTa, LSTb, LSTc, LSTd, DSLNT, SLNH and SLNH-II.

[0250] 14. The genetically modified cell according to any of the preceding items, wherein the one or more HMOs are fucosylated, preferably selected from the group consisting of: 2'FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II and LNDFH-III.

[0251] 15. The genetically modified cell according to any one of the preceding items, wherein the cell further comprises a nucleic acid sequence encoding a transporter protein capable of exporting the produced HMO into the extracellular medium.

[0252] 16. The genetically modified cell according to any one of the preceding items, wherein the modified cell is a microorganism.

[0253] 17. The genetically modified cell according to any of the preceding items, wherein the modified cell is a bacterium or a fungus.

[0254] 18. The genetically modified cell according to item 16 or 17, wherein the fungus is a yeast, preferably selected from the group consisting of Yarrowia lipolytica, Pichia pastoris and Saccharomyces cerevisiae.

[0255] 19. The genetically modified cell according to item 16 or 17, wherein the fungus is a filamentous fungus, preferably selected from Aspargillus sp., Fusarium sp. or Trichoderma sp.

[0256] 20. The genetically modified cell according to item 16 or 17, wherein the bacterium is selected from the group consisting of Escherichia sp., Bacillus sp., Lactobacillus sp., Corynebacterium sp., and Campylobacter sp.

[0257] 21. The genetically modified cell according to item 20, wherein the bacterium is Escherichia coli K12.

[0258] 22. A method for producing human milk oligosaccharides (HMO), comprising the following steps:

[0259] a) providing a genetically modified cell according to any one of items 1 to 21, and

[0260] b) cultivating the cell according to (a) in a suitable cell culture medium to produce the HMO.

[0261] 23. The method according to item 22, wherein the HMO is recovered from the culture broth and / or the biomass.

[0262] 24. The method according to item 22 or 23, wherein the method comprises culturing the genetically engineered cell in a culture medium containing one or more carbon sources selected from the group consisting of glucose, sucrose, fructose, xylose and glycerol.

[0263] 25. The method according to item 24, wherein the carbon source is glucose or sucrose.

[0264] 26. The method according to any one of items 22 to 25, wherein the culture medium in which the culturing is carried out contains lactose.

[0265] 27. The method according to any one of items 22 to 26, wherein the cultivation is a fed-batch fermentation or a feed-and-drain fermentation, wherein the carbon source is continuously fed to the fermentation broth.

[0266] 28. The method according to item 27, wherein the lactose is not present in the batch phase and is added to the culture during the feed phase.

[0267] 29. A method according to any one of items 22 to 28, wherein the genetically modified cell overexpresses citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc), and acetate formation in a culture grown in excess of a carbon source is at least 30% lower than in a method in which the genetically modified cell does not overexpress citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc).

[0268] 30. A method according to any one of items 22 to 27, wherein the genetically modified cell overexpresses citrate synthase (gltA) and expression of isocitrate lyase regulatory factor (iclR) is eliminated, and acetate formation in a culture grown in excess of a carbon source is at least 30% lower than a method in which the genetically modified cell does not overexpress citrate synthase (gltA) and expression of isocitrate lyase regulatory factor (iclR) is eliminated.

[0269] 31. A method according to any one of items 22 to 28, wherein the genetically modified cell according to items 1 to 18 produces less ethanol than a cell not containing said modification.

[0270] 32. The method of any one of items 22 to 31, wherein the one or more HMOs are selected from the group consisting of: LNT, LNnT, LNH, LNnH, pLNH, pLNnH, 2'FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II, LNDFH-III, F-pLNH, pLNnH, FLSTa, FLSTb, FLSTc, FLSTd, FSL, 3'SL, 6'SL, LSTa, LSTb, LSTc, LSTd, DSLNT, SLNH and SLNH-II.

[0271] Example

[0272] method

[0273] Unless otherwise stated, standard techniques, vectors, control sequence elements and other expression system elements known in the field of molecular biology are used for nucleic acid manipulation, conversion and expression. Such standard techniques, vectors and elements can be found in the following documents: Ausubel et al. (eds.), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch, & Maniatis (eds.), Molecular Cloning (1989) (Cold Spring Harbor Laboratory Press, NY); Berger & Kimmel, Methods in Enzymology 152: Guide to Molecular Cloning Techniques (1987) (Academic Press); Bukhari et al. (eds.), DNA Insertion Elements, Plasmids and Episomes (1977) (Cold Spring Harbor Laboratory Press, NY); Miller, JH Experiments in molecular genetics (1972.) (Coldspring Harbor Laboratory Press, NY).

[0274] The embodiments described below are chosen to illustrate the present invention and are not intended to limit the present invention in any way.

[0275] strain

[0276] The strain (genetically engineered cell) constructed in this application is based on Escherichia coli K-12DH1, and the genotype is: Fˉ, gyrA96, recA1, relA1, endA1, thi-1, hsdR17, supE44. The E. coli K-12DH1 strain was additionally modified to generate the MDO strain with the following modifications: lacZ: 1.5 kbp deletion, lacA: 0.5 kbp deletion, nanKETA: 3.3 kbp deletion, melA: 0.9 kbp deletion, wcaJ: 0.5 kbp deletion, mdoH: 0.5 kbp deletion, and the Plac promoter was inserted upstream of the gmd gene.

[0277] Methods for inserting or deleting a gene of interest into or from the E. coli genome are well known to those skilled in the art. Gene cassettes can be inserted into the E. coli chromosome using gene gorging using specific selectable marker genes and screening methods (see, e.g., Herring and Blattner 2004 J. Bacteriol. 186: 2673-81 and Warming et al. 2005 Nucleic Acids Res. 33 (4): e36).

[0278] The MDO strain was further engineered to generate a 2'FL production strain by chromosomal integration of two copies of the α-1,2-fucosyltransferase futC from Helicobacter pylori 26695 (homologous to NCBI Accession No. WP_080473865.1 with two additional amino acids (LG) at the C-terminus) under the control of the PglpF promoter and an additional copy of the colanic acid operon (gmd-wcaG-wcaH-wcaI-manC-manB) under the control of the PglpF promoter.

[0279] The genotypes of the background strain (MDO), the 2'FL strain, and the strains used in the Examples are shown in Table 11 below.

[0280] Table 11.

[0281]

[0282] Deep well assay

[0283] The strains were screened in 96 deep well plates using a 3 day protocol for 2'FL and a high sugar 2 day protocol for acetate assessment and growth rate assessment. During the first 24 hours, fresh pre-cultures were grown to high density and subsequently transferred to a medium that allowed product formation or induced acetate formation. More specifically, fresh pre-cultures were prepared using a basic minimal medium supplemented with magnesium sulfate, thiamine, and glucose. The pH was adjusted to pH 7.0 with NaOH. The pre-cultures were incubated at 34°C and 1000 rpm for 24 hours.

[0284] For 2'FL production, an aliquot of the pre-culture was transferred to a new deep-well plate with basal minimal medium (BMM, pH 7.5) to start the main culture. The new BMM was supplemented with thiamine and magnesium sulfate, 0.01% glucose, 0.5% lactose, 3.75% sucrose, thiamine, and 0.1 g / L sucrose hydrolase (Sigma-Aldrich). The 2'FL main culture was incubated at 30°C and 1000 rpm shaking for 48 hours.

[0285] For acetate production, aliquots of the pre-culture were transferred to new deep well plates with BMM medium (pH 7.5) containing thiamine and magnesium sulfate and 2.5% glucose. The acetate main culture was incubated at 30°C, 1000 prm for 24 hours. After the main culture incubation, it was boiled and centrifuged. The samples were analyzed by HPLC and an acetic acid assay kit (Megazyme).

[0286] For growth measurements, aliquots of the preculture were transferred to microtiter plates with BMM medium (pH 7.5) containing thiamine and magnesium sulfate and 2.5% glucose. The plates were incubated at 30° C., 840 rpm for 24 hours in a Varioskan. The absorbance at 600 nm was measured every 30 minutes.

[0287] Carbon-limited fed-batch fermentation

[0288] The pre-culture for batch feed fermentation is prepared in two steps. First, the strain from the freezer is inoculated into 10 ml of glucose minimal medium (GMM) (10 g / L NH4H2PO4, 5 g / L KH2PO4, 1 g / L citric acid, 2.35 g / LNaOH, 1.65 g / L KOH, 5 g / L K2SO4 and 5 mL / L trace mineral solution) in a shake flask, wherein containing 10 g / L glucose, 1 g / LMgSO4 and 4 μ g / mL thiamine. The pH value is adjusted to pH 7.0. The culture is cultured overnight at 33 ° C, 200 rpm. Then, the overnight culture is inoculated into 50 mL of GMM medium in a shake flask, wherein containing 10 g / L glucose, 1 g / L MgSO4 and 4 μ g / mL thiamine, so that OD reaches 0.25. After the precultures were grown to an OD of 2-3.5, they were used to inoculate fed-batch fermentations at an inoculation ratio of 2%.

[0289] exist High cell density, glucose-limited fed-batch fermentations were performed in a mini bioreactor system (Eppendorf) using a 100 mL initial volume of defined glucose minimal medium (GMM) mineral medium containing (NH4)H2PO4, KH2PO4, NaOH, KOH, K2SO4, citric acid, trace mineral solution, MgSO4, thiamine and glucose. The pH was adjusted to pH 6.8.

[0290] All main cultures started with a batch phase of 33°C, 25g / L glucose. The increase in pH triggered the start of the feed, indicating that the cells had consumed the initial glucose. Dissolved oxygen was maintained at 23% by stirring (minimum 700rpm) and airflow (6L / L / min). The pH was maintained at 6.8 by 14% NH4OH. A constant feed curve using a carbon-limited approach was used, with the feed medium containing glucose, lactose and all essential nutrients. Fermentation was stopped after 75 hours in the feed phase. 2'FL, biological wet mass (BWM) and OD (600nm) were measured from the fermentation broth.

[0291] Stress testing with large glucose pulses during a fed-batch process

[0292] In the above carbon limited fed batch fermentation process, a glucose pulse was added approximately 45-48 hours after the start of feeding by rapid injection using a high concentration solution and a sterile syringe to obtain a glucose concentration of 10 g / L (55 mM) in the fermentor. Samples of acetate and glucose were collected before the pulse, just after the pulse, and 10, 30, 50, 70 and 90 minutes after the pulse. Aeration and stirring were set to maximum when the glucose pulse was added, so that the dissolved oxygen level did not reach 0% or was reached only for a limited time. Acetic acid concentration was quantified from the supernatant by NMR, with 2'FL measured by HPLC.

[0293] Example 1 - Acetate reduction in deep well assay

[0294] In this example, the effects of mutations affecting the TCA cycle were investigated in terms of acetate reduction, growth rate under high glucose conditions, and the ability to maintain 2'FL expression under normal conditions.

[0295] The strains indicated in Table 11 were grown in the deep well assay described in the Methods section above. The results are shown in Table 12 below.

[0296] Table 12: Strain performance measured as growth rate (μmax), acetate production and 2'FL titer. 2'FL formation is presented relative to the control and is the average of three separate cultures.

[0297] Standard deviation of three individual cultures is shown as n=3.

[0298]

[0299] OE = Overexpression

[0300] Single overexpression of gltA (MP1) or ppc (MP4) reduced acetate production by 13.5% and 25%, respectively. However, overexpression of both gltA and ppc genes (MP5) caused a 49% reduction in acetate production. The combination of iclR deletion and gltA overexpression (MP3) caused a 73% reduction in acetate production. However, iclR deletion alone (MP2) only reduced acetate production by 5%, indicating a synergistic effect of the double mutation.

[0301] The production of 2'FL was not significantly affected in any of the strains, although strains with the iclR deletion (MP2 and MP3) appeared to show a positive effect on 2'FL production. The growth rate was also not significantly affected.

[0302] Example 2 - 2'FL and biomass production in fermentation of strains with gltA overexpression and / or iclR deletion

[0303] Based on the results from Example 1, it was decided to test strains with gltA overexpression and / or iclR deletion in a bioreactor setup.

[0304] The control strain and MP1, MP2 and MP3 strains were cultivated according to the carbon-restricted fermentation scheme in the above-mentioned method section. MP1, MP2 and MP3 were fermented twice (as duplicates), and the control was fermented three times (intriplicates). The results are shown in the following table 13 and are provided as relative values ​​with the control % 40 hours after the start of the feed. These values ​​are average values ​​calculated with respect to three replicates of the control strain or the test strain for two replicates, and are given as percentages. Figure 2 A and Figure 2 B also shows the results of this experiment for times between 0 and 40 h.

[0305] Table 13: Comparison of 2'FL production (g 2'FL / g glucose consumed) and biomass production (g biomass / g glucose consumed) in fed-batch fermentations.

[0306]

[0307] The performance of the unstressed mutants was compared 40 hours after the start of feeding (Table 13). 2'FL production was roughly similar or slightly higher compared to the control strain. Single overexpression of gltA or deletion of iclR (MP1 and MP2) increased 2'FL production on glucose by 7-8%, and the double mutant (MP3) increased by 5%.

[0308] Example 3: Stress Testing Using Large Glucose Pulses During a Fed-Batch Process

[0309] In this example, the fermentation of Example 2 was subjected to a glucose stress test using conditions similar to the large-scale fermentation.

[0310] After about 40 hours of feeding, the fermentation in Example 2 was subjected to a large glucose pulse (see stress test method above) to simulate the high glucose zone that occurs in industrial large-scale fermenters in order to stress the strain. Acetate formation was monitored for 90 minutes after the addition of the glucose pulse. 2'FL and biomass were also monitored periodically before (Example 2) and after the pulse. The results related to acetate formation are shown in Tables 14 and Figure 1 As shown in the figure, 2'FL and biomass are formed in Figure 2 Shown in.

[0311] Table 14: Average acetate formation after pulse addition of glucose to fermentations.

[0312]

[0313]

[0314] After the glucose pulse, all cultures accumulated acetate. After 90 minutes, the two gltA overexpression strains, MP1 and MP3, produced 33% and 64% less acetate than the control strain, with average acetate concentrations of 1.9 g / L and 1 g / L, respectively. The ΔiclR mutant (MP2) accumulated acetate close to the average of 2.6 g / L after 90 minutes, which was only 10% lower than the control strain, which accumulated 2.9 g / L acetate.

[0315] exist Figure 2 In A, it can be seen that before the glucose pulse (Example 2), the growth of the strains was quite similar, with slightly faster biomass development in the control strain. After the glucose pulse (indicated by the vertical grey dashed line), the growth of the control strain and the ΔiclR strain (MP2) dropped rapidly, indicating that these strains were not tolerant to the glucose pulse, which is consistent with Tables 14 and Figure 1 The immediate increase in acetate observed for these strains is consistent with that observed in 24 . High levels of acetate would obviously impair cell growth and most likely kill the cells during fermentation.

[0316] Figure 2 B shows 2'FL formation (g 2'FL / g glucose) as a percentage relative to maximum 2'FL production (MP1 at 97 hours). As described in Example 2, 2'FL formation was quite similar during the first 40 hours, with a slight increase in 2'FL formation in all mutant strains (see Table 13). However, as with the reduction in biomass, 2'FL formation in the control strain and the ΔiclR strain (MP2) also decreased rapidly, while 2'FL formation in cells overexpressing gltA did not seem to be affected by the glucose pulse.

Claims

1. A genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs), wherein the cell comprises the following modifications: a) overexpression of citrate synthase (gltA), and b) one or more heterologous nucleic acids encoding one or more glycosyltransferases, and c) at least one biosynthetic pathway for producing an activated sugar nucleotide capable of serving as a glycosyl donor for the glycosyltransferase of b).

2. The genetically modified cell according to claim 1, wherein the overexpression of citrate synthase is achieved by one or more of the following modifications: a) placing the native gltA gene under the control of a stronger promoter than the native promoter, or b) inserting into the cell a nucleic acid encoding a citrate synthase comprising or consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 80% identity with SEQ ID NO:

1.

3. The genetically modified cell according to any one of claims 1 or 2, wherein the cell further comprises at least one of the following modifications: i. Overexpression of phosphoenolpyruvate carboxylase (ppc), and / or ii. The function of isocitrate lyase regulator (iclR) is reduced or completely lost.

4. The genetically modified cell of claim 3, wherein the overexpression of the phosphoenolpyruvate carboxylase is achieved by one or more of the following modifications: a) placing the native ppc gene under the control of a promoter that is stronger than the native promoter, or b) inserting into the cell a nucleic acid encoding a phosphoenolpyruvate carboxylase, wherein the phosphoenolpyruvate carboxylase comprises or consists of the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence having at least 80% identity with SEQ ID NO:

2.

5. The genetically modified cell according to claim 3 or 4, wherein the gene encoding the isocitrate lyase regulator (iclR) is deleted or becomes dysfunctional.

6. A genetically modified cell according to any one of the preceding claims, wherein overexpression of the gltA and / or ppc gene is controlled by a promoter selected from a promoter sequence having a nucleic acid sequence as shown in Table 10, preferably selected from a promoter sequence of SEQ ID NO: 17 (PglpF) or SEQ ID NO: 26 (Plac) or SEQ ID NO: 14 (PmglB_UTR70) or SEQ ID NO: 15 (PglpA_70UTR) or SEQ ID NO: 16 (PglpT_70UTR) or SEQ ID NO: 29 (Pcon3_70UTR), or variants thereof.

7. A genetically modified cell according to any one of the preceding claims, wherein a nucleic acid encoding citrate synthase (gltA) and / or phosphoenolpyruvate carboxylase (ppc) is inserted into the genome of the genetically modified cell.

8. The genetically modified cell of any one of the preceding claims, wherein the one or more glycosyltransferases are selected from an enzyme having the activity of α-1,2-fucosyltransferase, α-1,3-fucosyltransferase, α-1,3 / 4-fucosyltransferase, α-1,4-fucosyltransferase α-2,3-sialyltransferase, α-2,6-sialyltransferase, β-1,3-N-acetylglucosaminetransferase, β-1,6-N-acetylglucosaminetransferase, β-1,3-galactosyltransferase, and β-1,4-galactosyltransferase.

9. The genetically modified cell of any one of the preceding claims, wherein the glycosyltransferase is a fucosyltransferase and at least one of the genes necessary for de novo synthesis of GDP-fucose in the biosynthetic pathway is overexpressed.

10. The genetically modified cell of any one of the preceding claims, wherein the one or more HMOs are selected from the group consisting of: LNT, LNnT, LNH, LNnH, pLNH, pLNnH, 2'FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II, LNDFH-III, F-pLNH, pLNnH, FLSTa, FLSTb, FLSTc, FLSTd, FSL, 3'SL, 6'SL, LSTa, LSTb, LSTc, LSTd, DSLNT, SLNH, and SLNH-II.

11. The genetically modified cell according to any one of the preceding claims, wherein the one or more HMOs are fucosylated, preferably selected from the group consisting of: 2'FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II and LNDFH-III.

12. The genetically modified cell of any one of the preceding claims, wherein the cell further comprises a nucleic acid sequence encoding a transporter protein capable of exporting the produced HMOs into the extracellular medium.

13. A genetically modified cell according to any one of the preceding claims, wherein the modified cell is a microorganism.

14. A genetically modified cell according to any one of the preceding claims, wherein the modified cell is a bacterium or a fungus.

15. The genetically modified cell according to claim 13 or 14, wherein the fungus is a yeast, preferably selected from the group consisting of Yarrowia lipolytica, Pichia pastoris and Saccharomyces cerevisiae.

16. The genetically modified cell according to claim 13 or 14, wherein the fungus is a filamentous fungus, preferably selected from the genus Aspargillus sp., Fusarium sp. or Trichoderma sp.

17. The genetically modified cell according to claim 13 or 14, wherein the bacterium is selected from the group consisting of Escherichia sp., Bacillus sp., Lactobacillus sp., Corynebacterium sp., and Campylobacter sp.

18. A method for producing human milk oligosaccharides (HMOs), comprising the steps of: a) providing a genetically modified cell according to any one of claims 1 to 17, and b) cultivating the cell according to (a) in a suitable cell culture medium to produce the HMO.

19. The method according to claim 18, wherein the HMO is recovered from the culture broth and / or the biomass.

20. The method of claim 18 or 19, wherein the method comprises culturing the genetically engineered cell in a medium containing one or more carbon sources selected from the group consisting of glucose, sucrose, fructose, xylose and glycerol.

21. The method of claim 20, wherein the carbon source is glucose or sucrose.

22. The method according to any one of claims 18 to 21, wherein the medium in which the culturing is carried out contains lactose.

23. The method according to any one of claims 18 to 22, wherein the cultivation is a fed-batch fermentation or a feed-and-drain fermentation, wherein the carbon source is continuously fed to the fermentation broth.

24. The method of claim 23, wherein the lactose is not present in the batch phase and is added to the culture during the feed phase.

25. The method of any one of claims 18 to 24, wherein the genetically modified cells overexpress citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc), and acetate formation in a culture grown in excess of a carbon source is at least 30% lower than in a method in which the genetically modified cells do not overexpress citrate synthase (gltA) and phosphoenolpyruvate carboxylase (ppc).

26. The method of any one of claims 18 to 24, wherein the genetically modified cell overexpresses citrate synthase (gltA) and expression of isocitrate lyase regulatory factor (iclR) is eliminated, and acetate formation in a culture grown in excess of a carbon source is at least 30% lower than in a method in which the genetically modified cell does not overexpress citrate synthase (gltA) and expression of isocitrate lyase regulatory factor (iclR) is eliminated.

27. The method of any one of claims 18 to 24, wherein the genetically modified cells of claims 1 to 15 produce less ethanol than cells not containing the modifications of claim.

28. The method of any one of claims 18 to 27, wherein the one or more HMOs are selected from the group consisting of: LNT, LNnT, LNH, LNnH, pLNH, pLNnH, 2'FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNFP-VI, LNDFH-I, LNDFH-II, LNDFH-III, F-pLNH, pLNnH, FLSTa, FLSTb, FLSTc, FLSTd, FSL, 3'SL, 6'SL, LSTa, LSTb, LSTc, LSTd, DSLNT, SLNH and SLNH-II.

Citation Information

Patent Citations

  • Oligosaccharide production

    WO2015197082A1

  • Separation of oligosaccharides from fermentation broth

    WO2017152918A1

  • Separation of oligosaccharides from fermentation broth

    WO2017182965A1

  • Nucleic acid construct for in vitro and in VIVO gene expression

    WO2019123324A1

  • Nucleic acid construct comprising 5' UTR stem-loop for in vitro and in VIVO gene expression

    WO2020255054A1